<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001495" GROUP_ID="AIRWAYS" ID="828699100408475207" MERGED_FROM="" MODIFIED="2009-05-26 12:04:40 +0200" MODIFIED_BY="Toby Lasserson" NOTES="&lt;p&gt;Exported from Review Manager 4.2.1&lt;br&gt;14/05/2002&lt;br&gt;Review updated with latest search for trials and one study excluded (Cook 2001). &lt;/p&gt;&lt;p&gt;Felix &amp;amp; Piersante&lt;br&gt;---------------------------------------------&lt;br&gt;03/04/2000&lt;br&gt;ALL OUTSTANDING ISSUES RESOLVED BETWEEN THE REVIEWERS (P SESTINI &amp;amp; F RAM) AND P POOLE (CAG ASSIGNED EDITOR).&lt;/p&gt;&lt;p&gt;03/04/2000&lt;br&gt;Hi Felix and Piersante&lt;/p&gt;&lt;p&gt;This is looking GOOD!&lt;/p&gt;&lt;p&gt;I can assure you that this is not an endless review...probably one of the&lt;br&gt;quickest!&lt;/p&gt;&lt;p&gt;See below-I have replied to you in CAPS below-no major issues with what you&lt;br&gt;say but have made some suggestions/clarified my comments. Mainly the issues&lt;br&gt;revolve around clarification/sematics so we are nearly there!&lt;/p&gt;&lt;p&gt;I hope you have spell checked both my changes and yours as I found a few&lt;br&gt;more errors!&lt;/p&gt;&lt;p&gt;Once it is finally refined suggest you send it off to Paul Jones ASAP to see&lt;br&gt;if we can make the next deadline.&lt;/p&gt;&lt;p&gt;Please send me a copy of your final version?&lt;/p&gt;&lt;p&gt;You may wish to incorporate this email into the notes section as &amp;quot;history&amp;quot;,&lt;br&gt;or at least write in that you have contacted me again before sending off.&lt;/p&gt;&lt;p&gt;On a social note, will either of you be at COPD 2000 in Birmingham as I am&lt;br&gt;coming for that conference-it would be nice to catch up. I hav submitted my&lt;br&gt;fluvax in COPD review as a poster.&lt;/p&gt;&lt;p&gt;Its been nice working with you-what is the next one, dare I ask?&lt;/p&gt;&lt;p&gt;Anyway, enuf chat&lt;/p&gt;&lt;p&gt;Best wishes&lt;/p&gt;&lt;p&gt;Phillippa&lt;/p&gt;&lt;p&gt;&lt;br&gt;----- Original Message -----&lt;br&gt;From: Piersante Sestini &amp;lt;sestini@unisi.it&amp;gt;&lt;br&gt;To: Phillippa Poole and Paul Gilkison &amp;lt;psquared@iconz.co.nz&amp;gt;&lt;br&gt;Sent: Friday, March 31, 2000 1:40 AM&lt;br&gt;Subject: Cochrane Review&lt;/p&gt;&lt;p&gt;&lt;br&gt;&amp;gt; Dear Philippa,&lt;br&gt;&amp;gt;&lt;br&gt;&amp;gt; We are revising the review according to your last suggestions. We already&lt;br&gt;&amp;gt; fixed most of it. However, there are a few points&lt;br&gt;&amp;gt; that we should discuss further because we may have not understood your&lt;br&gt;&amp;gt; changes or you may have misunderstood some of our text (in which case we&lt;br&gt;&amp;gt; may have to make it more clear anyway!).&lt;br&gt;&amp;gt;&lt;br&gt;&amp;gt; First of all, we certainly agree that you have contributed substantially&lt;br&gt;in&lt;br&gt;&amp;gt; the development of the protocol and in the revision of the review. So,&lt;br&gt;&amp;gt; although we may not agree that *any* editor should be included as an&lt;br&gt;author&lt;br&gt;&amp;gt; of each review, we have no doubt that you deserve it. We also realized&lt;br&gt;that&lt;br&gt;&amp;gt; the work of Dr. Stewart  Robinson and Elisabetta Renzoni, was&lt;br&gt;&amp;gt; insufficiently recognized in the acknowledgement section, and we decided&lt;br&gt;&amp;gt; that they should be listed among the authors of the review.&lt;/p&gt;&lt;p&gt;I AM VERY HONOURED, THANKS.&lt;/p&gt;&lt;p&gt;&amp;gt; Here are the few points that need clarification (all other points are&lt;br&gt;being&lt;br&gt;&amp;gt; modified according to your indications):&lt;br&gt;&amp;gt;   (The original text from your revised review is quoted after &amp;quot;&amp;gt;&amp;quot;):&lt;br&gt;&amp;gt;&lt;br&gt;&amp;gt; i) Synopsis:&lt;br&gt;&amp;gt;   &amp;gt;THIS REVIEW SHOWS THAT regular use FOR AT LEAST A WEEK of inhaled&lt;br&gt;&amp;gt; MEDICINES THAT RELIEVE AIRWAYS&lt;br&gt;&amp;gt;   &amp;gt; OBSTRUCTION CAN improve the symptoms associated with COPD in most&lt;br&gt;&amp;gt; patients but not all.&lt;br&gt;&amp;gt;&lt;br&gt;&amp;gt; We find the term &amp;quot;medicines that relieve airways obstruction&amp;quot; to be too&lt;br&gt;&amp;gt; broad and possibly imprecise , as we did not analyze other&lt;br&gt;bronchodilators,&lt;br&gt;&amp;gt; such as anti-cholinergic drugs. We suggest &amp;quot;beta2 agonist&lt;br&gt;bronchodilators&amp;quot;.&lt;br&gt;&amp;gt; All other changes are accepted.&lt;/p&gt;&lt;p&gt;THE SYNOPSIS IS FOR THE LAY PUBLIC ?USE &amp;quot;INHALED BETA 2 MEDICINES&amp;quot;&lt;/p&gt;&lt;p&gt;&amp;gt; ii)Reviewers' conclusions:&lt;br&gt;&amp;gt;   &amp;gt; THERE IS NO EVIDENCE IN THIS REVIEW OF AN INCREASE IN ADVERSE&lt;br&gt;&amp;gt; EFFECTS,  HOWEVER  large scale, parallel, ...&lt;br&gt;&amp;gt;&lt;br&gt;&amp;gt; We found that this could be misleading, as the point here is not the lack&lt;br&gt;&amp;gt; of evidence (or inconsistent data), but the lack of data itself. We&lt;br&gt;&amp;gt; suggest: &amp;quot;Although there is no evidence in this review of an increase in&lt;br&gt;&amp;gt; adverse effects, none of the studies was of sufficient lenght or size to&lt;br&gt;&amp;gt; provide reliable information on this topic. Therefore, large scale.......&amp;quot;&lt;br&gt;OK&lt;/p&gt;&lt;p&gt;&amp;gt; iii)Results&lt;br&gt;&amp;gt; Spirometry&lt;br&gt;&amp;gt;   &amp;gt;Although spirometry was carried out ?AT THE END OF THE TREATMENT PERIOD&lt;br&gt;&amp;gt; before and after BRONCHODILATOR in all&lt;br&gt;&amp;gt;   &amp;gt; studies, data was not reported by all studies.&lt;br&gt;&amp;gt;&lt;br&gt;&amp;gt; You correctly ask in the notes whether it refers to pre- and&lt;br&gt;&amp;gt; post-bronchodilator. No, we were referring to initial baseline. In some&lt;br&gt;&amp;gt; studies, at the end of treatment, it was measured in some studies only&lt;br&gt;&amp;gt; after the last treatment administration. It could left as you suggest,&lt;br&gt;&amp;gt; changing &amp;quot;all studies&amp;quot; with  &amp;quot;most studies&amp;quot;.&lt;br&gt;JUST SO LONG AS IT IS CLEAR WHAT IS BEING MEASURED AND WHEN-MAYBE ADD SOME&lt;br&gt;WORDS TO THE HEADINGS IN METAVIEW&lt;/p&gt;&lt;p&gt;&amp;gt; iv)Walking test&lt;br&gt;&amp;gt;   &amp;gt;IN two studies THERE WAS A SUGGESTION OF AN  increase in MEAN 6MW&lt;br&gt;distance&lt;br&gt;&amp;gt;&lt;br&gt;&amp;gt; You also say in the notes:&lt;br&gt;&amp;gt;   &amp;gt;Walk Test-you can't say that there were large increases as the results&lt;br&gt;&amp;gt; were insignificant. There was obviously a large amount of&lt;br&gt;&amp;gt;   &amp;gt;variation to give the largish SDs.&lt;br&gt;&amp;gt;&lt;br&gt;&amp;gt; No, the difference in these two original studies was really significant,&lt;br&gt;&amp;gt; using paired comparison. We failed to find significance in the same&lt;br&gt;studies&lt;br&gt;&amp;gt; because the parallel approach that we were forced to use was less&lt;br&gt;&amp;gt; sensitive. We suggest &amp;quot;an increase in 6MW was reported&amp;quot;. The difference in&lt;br&gt;&amp;gt; the other study with 12MW was not significant, and this could be pointed&lt;br&gt;&amp;gt; out as you suggest.&lt;/p&gt;&lt;p&gt;THE HANSEN STUDY CARRIES MORE WT AS IT IS BIGGER AND HAS RELATIVELY SMALLER&lt;br&gt;SD. WHAT ABOUT SOMETHING LIKE&lt;br&gt;Three studies reported the effect of b2 on 6MW. Two of these showed a&lt;br&gt;clinically significant (&amp;gt;30m) increase in walk distance , however, the&lt;br&gt;third, a larger study which carried more weight in the meta analysis, showed&lt;br&gt;no significant difference. Overall, therefore, there was no statistically or&lt;br&gt;clinically significant effect of b2 on 6MW.&lt;/p&gt;&lt;p&gt;&lt;br&gt;&amp;gt; v)Discussion:&lt;br&gt;&amp;gt;   &amp;gt;Although we restricted our analysis to PATIENTS DEFINED BY THEIR&lt;br&gt;&amp;gt; INVESTIGATORS AS HAVING COPD,  study populations&lt;br&gt;&amp;gt;&lt;br&gt;&amp;gt; This is not true. We restricted our analysis to patients fulfiilling the&lt;br&gt;&amp;gt; ATS criteria for COPD, not &amp;quot;defined by the investigators as having COPD&amp;quot;.&lt;br&gt;A&lt;br&gt;&amp;gt; response to bronchodilators does not exclude the diagnosis, as long as&lt;br&gt;this&lt;br&gt;&amp;gt; is only partial. I suggest  to resume the original text, which seemed well&lt;br&gt;&amp;gt; balanced. We may add that we carefully excluded studies including patients&lt;br&gt;&amp;gt; reported to have asthma&lt;br&gt;&amp;gt; What we are saying here is that despite they all fulfill the definition,&lt;br&gt;&amp;gt; the requirements for bronchodilator response varied slightly between&lt;br&gt;&amp;gt; studies, but this should not matter much. We could keep your further&lt;br&gt;&amp;gt; changes later in the sentence.&lt;br&gt;&amp;gt;&lt;br&gt;&amp;gt; This might answer also your question in the notes:&lt;br&gt;&amp;gt;   &amp;gt;In the Additional table describing the studies..did Tandon actually&lt;br&gt;have&lt;br&gt;&amp;gt; reversibility &amp;gt;15% as a criteria? This suggests the patients in&lt;br&gt;&amp;gt;   &amp;gt;this study may have a large asthmatic component.&lt;/p&gt;&lt;p&gt; SEMANTICS! THE INVETIGATORS DECIDED IF THEY FULFILLED THE ATS CRITERIA! ATS&lt;br&gt;CRITERIA SAY THERE CAN BE PARTIAL REVERISBILITY. I'M NOT SURE THAT &amp;gt;15% IS&lt;br&gt;THE SAME AS THAT! &amp;gt;15% COULD BE 80%! I THINK YOU NEED TO DEFEND THE&lt;br&gt;INCLUSION OF THIS TANDON STUDY AS OTHERS MAY QUESTION THIS AS WELL.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&amp;gt; vi)&lt;br&gt;&amp;gt;   &amp;gt;THE SHORT DURATION OF THE STUDIES MEAN THAT IT IS UNLIKELY THERE WAS&lt;br&gt;ANY&lt;br&gt;&amp;gt; MAJOR DISEASE PROGRESSION&lt;br&gt;&amp;gt;   &amp;gt;OVER TIME.&lt;br&gt;&amp;gt;&lt;br&gt;&amp;gt; This sentence does not seems to be clear. Maybe  you mean: &amp;quot;The short&lt;br&gt;&amp;gt; duration ..... made them unsuitable to evaluate any effect on disease&lt;br&gt;&amp;gt; progression over time&amp;quot;?&lt;/p&gt;&lt;p&gt;WHAT IS INTENDED IS THAT YOU WOULDN'T EXPECT TO SEE ANY DETERIORATION IN&lt;br&gt;LUNG FUNCTION OVER TIME DURING THE SHORT DURATION OF THESE STUDIES. PERHAPS&lt;br&gt;OMIT OR PUT IT DOWN LATER WHEN YOU ARE DISCUSSING CROSS OVER STUDIES. THIS&lt;br&gt;IS GOOD, AS DISEASE PROGRESSION IS A PROBLEM FOR CROSS OVER TRIALS. (IT&lt;br&gt;RESULTS IN UNMATCHED BASELINES)&lt;/p&gt;&lt;p&gt;&amp;gt; vii)&lt;br&gt;&amp;gt;   &amp;gt;Although we were forced to combine breathlessness scores using&lt;br&gt;&amp;gt; standardised means to overcome the different scales used in the&lt;br&gt;&amp;gt;   &amp;gt;included studies, it should be noted that the improvement in the score&lt;br&gt;&amp;gt; was consistent across the many different studies (?COMMENT &amp;gt;ON&lt;br&gt;HETEROGENEITY&lt;br&gt;&amp;gt;&lt;br&gt;&amp;gt; You add in the notes:&lt;br&gt;&amp;gt;   &amp;gt;The result 01 21 03..daily breathlessness is heterogenous-?explain by&lt;br&gt;&amp;gt; type of scale used / or type of agent . This is an important&lt;br&gt;&amp;gt;   &amp;gt;outcome to explore further, since it is THE major finding of the&lt;br&gt;review.&lt;br&gt;&amp;gt; should discuss a little in discussion.&lt;br&gt;&amp;gt;&lt;br&gt;&amp;gt; No, it is the SCALES on which breathlessness is measured which are&lt;br&gt;&amp;gt; heterogeneous. This is described in the results. Here we are commenting&lt;br&gt;the&lt;br&gt;&amp;gt; opposite: despite being expressed on different scales, the response seems&lt;br&gt;&amp;gt; rather homogeneous across different studies. Maybe you are being mislead&lt;br&gt;by&lt;br&gt;&amp;gt; metaview 3.1 in which, if you fail to convert the&lt;br&gt;&amp;gt; statistics to SMD you are actually seeing results in WMD. Still, the chi&lt;br&gt;&amp;gt; square is 6.02 with 3 DF and the upper limit at 0.05 is 7.81, which means&lt;br&gt;&amp;gt; that our value should be greather than 7.81 to be heterogeneous.&lt;/p&gt;&lt;p&gt;OK-POINT TAKEN. PAUL J MAY COMMENT FURTHER&lt;/p&gt;&lt;p&gt;&amp;gt; viii) implications for practice&lt;br&gt;&amp;gt;&lt;br&gt;&amp;gt;   &amp;gt;The bronchodilator response (or lack of it) after a single&lt;br&gt;&amp;gt; administration is a poor predictor of long term clinical response (IS THIS&lt;br&gt;&amp;gt;   &amp;gt; ADDRESSED IN THIS REVIEW?OMIT&lt;br&gt;&amp;gt;&lt;br&gt;&amp;gt; We think that this point has been addressed: as we pointed out before, the&lt;br&gt;&amp;gt; response appears unaffected by the selection of more or less responsive&lt;br&gt;&amp;gt; patients in the included studies. Other relevant studies are quoted in the&lt;br&gt;&amp;gt; discussion. We suggest to mantain the sentence, as it has important&lt;br&gt;&amp;gt; implication in practice..&lt;/p&gt;&lt;p&gt;OK.AGREE IT IS AN IMPORTANT PRACTICE POINT. I WOULDN'T AGREE THAT 1-6 WEEKS&lt;br&gt;IS LONG TERM. SUGGEST USE THE WORD &amp;quot;LONGER&amp;quot; . ONE WOULD OBVIOUSLY LIKE TO&lt;br&gt;SEE QOL DATA, ALHTOUGH THE PATIENT PREFERENCE DATA IS PRETTY COMPELLING!&lt;br&gt;LEAVE THE SENTENCE IN.&lt;/p&gt;&lt;p&gt;&lt;br&gt;&amp;gt; ix)&lt;br&gt;&amp;gt;   &amp;gt;More appropriate in other groups of patients ALTHOUGH THIS QUESTION WAS&lt;br&gt;&amp;gt; NOT SPECIFICALLY ADDRESSED IN THIS&lt;br&gt;&amp;gt;   &amp;gt;REVIEW. THERE WAS NO EVIDENCE IN THIS REVIEW OF AN INCREASE IN ADVERSE&lt;br&gt;&amp;gt; EFFECTS, ALTHOUGH NUMBERS OF&lt;br&gt;&amp;gt;   &amp;gt;PATIENTS WERE VERY SMALL&lt;br&gt;&amp;gt;&lt;br&gt;&amp;gt; we could add &amp;quot;and follow-up was equally short&amp;quot;&lt;/p&gt;&lt;p&gt;GOOD SUGGESTION&lt;/p&gt;&lt;p&gt;&amp;gt; x) Implications for research&lt;br&gt;&amp;gt;   &amp;gt; THESE STUDIES HAVE NOW BEEN CONDUCTED FOR long-acting beta-2 agonistS&lt;br&gt;&amp;gt; AND anticholinergic AGENTS&lt;br&gt;&amp;gt;&lt;br&gt;&amp;gt; Maybe &amp;quot;in part conducted&amp;quot;. We are not aware of placebo-controlled&lt;br&gt;long-term&lt;br&gt;&amp;gt; studies with these drugs reporting on survival or monitoring side effects:&lt;br&gt;&amp;gt; are they really available?&lt;/p&gt;&lt;p&gt;OK. WHAT ABOUT LUNG HEALTH STUDY AND THE PAUL JONES' SALMETEROL STUDY? AGREE&lt;br&gt;THEY DON'T INCLUDE ALL THE ENDPOINTS YOU ARE INTERESTED IN, AND NOT POWERED&lt;br&gt;FOR MORTALITY BUT LARGE ENOUGH, AND CERTAINLY LARGER AND BETTER CONDUCTED&lt;br&gt;THAN THE B2 AGONIST STUDIES.&lt;/p&gt;&lt;p&gt;&amp;gt; Let us know your opinion/suggestions and, as soon we reach a consensus on&lt;br&gt;&amp;gt; these few remaining points, we could eventually release this endless&lt;br&gt;review!&lt;br&gt;HOPE THATS  ALL CLEAR!&lt;br&gt;GOOD LUCK WITH THE REST OF THE PROCESS&lt;/p&gt;&lt;p&gt;&lt;br&gt;PHILLIPPA :)&lt;/p&gt;&lt;p&gt;&lt;br&gt;17/03/2000&lt;br&gt;Dear Phillippa we are afarid we do not agree with all of your comments and suggestions and do consider that a few of your comments were unnecessary and irrelevant.  We have made our comments in CAPS after your comments below.  &lt;/p&gt;&lt;p&gt;13/03/00&lt;br&gt;Dear Felix and Piersante&lt;/p&gt;&lt;p&gt;This looks really good. I would suggest you consider the following. If you are happy with what I have suggested...correct/ put back to normal text and send off to Paul Jones. If you are not, get back to me first.&lt;br&gt;At CAG we have discussed the inclusion of the editor as an author on reviews as a matter of course. I am a litlle reluctant to ask for this but feel that I have contributed considerably to get this one done. Have a think about whether you think my contribution warrants author status! &lt;/p&gt;&lt;p&gt;WE BELIEVE THAT THIS IS AN UNFAIR AND UNREALISTIC APPROACH OF CAG THAT EDITORS NAMES BE ADDED TO THE AUTHORS LIST AS A MATTER OF COURSE.   WE BELIEVE THAT WHEN AND IF THE CAG EDITOR HAS CARRIED OUT SUFFICIENT WORK IN ORDER TO WARRANT THEIR NAME TO BE ADDED TO THE AUTHOR LIST AND THE SAME AMOUNT AS THE OTHER AUTHORS (AS JUDGED BY THE REVIEWERS WHO DO MOST OF THE WORK) THAN IT WOULD WARRANT THE ADDITION OF THE EDITORS NAME TO THE LIST.  IN THIS CASE AND AS REQUESTED BY YOURSELF, WE SHALL ADD YOUR NAME TO THE LIST OF AUTHORS.  &lt;/p&gt;&lt;p&gt;Grammatical changes throughout, I have changed and haven't listed them all-hope that is OK. &lt;/p&gt;&lt;p&gt;OK&lt;/p&gt;&lt;p&gt;Questions/comments-very few!:&lt;/p&gt;&lt;p&gt;TEXT CHANGES SUGGESTED IN CAPS..SUGGEST YOU READ THROUGH FIRST BEFORE LOOKING AT THE COMMENTS TOO MUCH AS I HAVE HAVE ALREADY MADE SOME SUGGESTIONS...LET ME KNOW IF YOU HAVE MAJOR PROBLEMS WITH THEM. &lt;/p&gt;&lt;p&gt;Can you CONFIRM that  &amp;quot;prebronchodilator&amp;quot; is actually at the end of the study period , but before administration of the final dose? Please see results section where I have suggested  clarification.&lt;/p&gt;&lt;p&gt;CONFIRMED&lt;/p&gt;&lt;p&gt;In these RCTs presumably the treatments were were given db and what was actually randomised was the order in which they were given. This could be emphasised more. If the design is db, with a washout, over a short period, this should strengthen your case to do the analysis as per parallel studies. &lt;/p&gt;&lt;p&gt;DONE&lt;/p&gt;&lt;p&gt;Some hyper text links seem to be missing for the references. Could you change these?&lt;/p&gt;&lt;p&gt;FIXED&lt;/p&gt;&lt;p&gt;Numbers of comparisons jumps from 21-27-need to fix&lt;/p&gt;&lt;p&gt;FIXED&lt;/p&gt;&lt;p&gt;You actually did do sensitivity analysis by medicine, even though you say that you didn't (because the results were all homogeneous).&lt;/p&gt;&lt;p&gt;OK&lt;/p&gt;&lt;p&gt;The result 01 21 03..daily breathlessness is heterogenous-?explain by type of scale used / or type of agent . This is an important outcome to explore further, since it is THE major finding of the review. should discuss a little in discussion.  &lt;/p&gt;&lt;p&gt;TOTALLY DISAGREE: THIS RESULT IN NOT HETEROGENOUS.  WE BELIEVE YOU ARE USING META-VIEW 3.1 (AS WE ARE ALL SUPPOSE TO) BUT YOU HAVE FORGOTTEN TO CONVERT THE STATISTIC TO SMD AND ARE VIEWING OUR RESULT IN WMD, BUT IF YOU ARE NOT THAN WE STILL FAIL TO SEE HOW YOU THINK THIS RESULT IS HETEROGENOUS AS THE VALUE IN META-VIEW 3.1 OR 4.04 IS 6.02 FOR CHI SQUARE (WITH 3 DF) AND THE UPPER PERCENTILE WITH 3 DF AT 0.050 IS IN THE CHI SQUARE TABLE IS 7.81.  OUR VALUE NEEDS TO BE GREATER THAN 7.81 IN ORDER FOR THIS RESULT TO BE HETEROGENOUS.  WE BELIEVE THE AMOUNT OF DISCUSSION ALREADY ON THIS OUTCOME IS SUFFICIENT UNLESS YOU ARE REFERRING TO THE HETEROGENOUS ISSUE, WHICH SHOULD NO LONGER BE AN ISSUE AS PER OUR EXPLANATION ABOVE.  FURTHERMORE WE DO NOT THINK THE TERM HETEROGENOUS SHOULD BE USED TO EXPLAIN THE DIFFERENT SCALES USED AS IT COULD BE MISLEADING, IT IS A WELL KNOWN FACT THAT DIFFERENT SCALES ARE USED FOR SUCH THIS OUTCOME, SINCE THERE ARE SO MANY OF DIFFERENT TYPES OF SCALES.    &lt;/p&gt;&lt;p&gt;In the Additional table describing the studies..did Tandon actually have reversibility &amp;gt;15% as a criteria? This suggests the patients in this study may have a large asthmatic component.&lt;/p&gt;&lt;p&gt;ACCORDING TO THE ATS GUIDELINES &amp;gt;15% REVERSIBILITY DOES NOT CONSTITUTE ASTHMA AS LONG AS THIS REVERSIBILITY IS ONLY PARTIAL.. ALL PATIENTS MET THE ATS CRITERIA FOR COPD.  &lt;/p&gt;&lt;p&gt;Walk Test-you can't say that there were large increases as the results were insignificant. There was obviously a large amount of variation to give the largish SDs.&lt;/p&gt;&lt;p&gt;WE CAN, BEACAUSE WE ARE NOT TALKING ABOUT THE OVERALL RESULT IN META-VIEW BUT THE INDIVIDUAL STUDIES WHICH  HAD  SIGNIFICANT INCREASES, HOWEVER POINT MADE EVEN CLEARER IN TEXT.  &lt;/p&gt;&lt;p&gt;That is all!&lt;/p&gt;&lt;p&gt;I have left previous comments below for reference..&lt;/p&gt;&lt;p&gt;08/02/2000&lt;br&gt;AS SUGGESTED REPONSES IN CAPS, BELOW.&lt;/p&gt;&lt;p&gt;21/12/99&lt;br&gt;Felix and Piersante-well done! You have worked very hard and this is very readable and coherent!  This is a very good review.Felix I have given PB a copy.&lt;/p&gt;&lt;p&gt;I have made some minor changes already to this version (spelling/grammar) but there are more major things that I will ask you to work through if you have time over Christmas. I am away till 10th Jan. We should be aiming to get this to Paul Jones by the end of Jan hopefully to go on the next version of the library although it may be a bit tight because of the need to get peer review &lt;/p&gt;&lt;p&gt;My comments (please let me know if you disagree):&lt;br&gt;Please spell check..there are a few spelling mistakes/plus grammar errors.&lt;br&gt;Synopsis-should only be 3 sentences long-designed for a lay person to read..I can do this for you. &lt;/p&gt;&lt;p&gt;DONE&lt;/p&gt;&lt;p&gt;Abstract-likewise should only be about 300 words. Main results only. Suggest you look a the long acting b agonist review for guidance&lt;/p&gt;&lt;p&gt;DONE, BUT OTHER 'FIXED' SUB-HEADINGS BESIDES RESULTS HAS TO BE ALSO COMPLETED.&lt;/p&gt;&lt;p&gt;Description of studies. p.7. It would be helpful for you to describe more about the studies, e.g. that they were all cross over, that they excluded asthma, setting, age of participants, severity of disease etc. (see long acting b agonist for guidance) . Also what drugs, doses, frequency, inhaler device used , duration of therapy. ? run in and washout period, /compliance-people don't go to the back!&lt;/p&gt;&lt;p&gt;DONE IN TEXT BUT (GETTING TOO LARGE) SO ADDED AN ADDITIONAL TABLE IN 'ADDITIONAL TABLE' SECTION IF PEOPLE ARE INTERESTED IN MORE DETAIL THEY WILL HAVE TO GO TO THIS TABLE (AS POINTED OUT IN TEXT).  &lt;/p&gt;&lt;p&gt;Could mention small sample sizes, old compounds here instead of in Results.&lt;/p&gt;&lt;p&gt;DONE&lt;/p&gt;&lt;p&gt;Methodological p.7 What were the Jadad scores and the concealment. How much agreement was there? &lt;/p&gt;&lt;p&gt;NOT USED THEREFORE DELETED AND ANY RELEVANCE TO IT.  &lt;/p&gt;&lt;p&gt;Results P.8&lt;/p&gt;&lt;p&gt;you say 56 papers were included in this review, but then 43 were excluded. It may be better to say that 56 were RCTs of long term use of short acting b agonists in COPD. However............a further 43 were excluded because.... YOu should state exactly how many papers were included in the review (not &amp;quot;a few!&amp;quot;)(Did you write for more data from any authors?).&lt;/p&gt;&lt;p&gt;DONE, AUTHORS HAVE BEEN WRITTEN TO AND MENTIONED IN TEXT THAT WE WILL UPDATE WHEN AND IF WE GET RESPONSES.&lt;/p&gt;&lt;p&gt;include p values in the text (not everyone understands CIs)&lt;/p&gt;&lt;p&gt;DONE&lt;/p&gt;&lt;p&gt;comment on heterogeneity-or lack of it...they are pretty good&lt;/p&gt;&lt;p&gt;THANKS&lt;/p&gt;&lt;p&gt;generally avoid judgemental comments like :&amp;quot;PEFR is better&amp;quot; in the results section. The readers should be able to look at this section and decide for themselves. Enter results, explanations and comparisons, but not opinions here.&lt;/p&gt;&lt;p&gt;WE DID NOT SAY THAT &amp;quot;PEFR IS BETTER&amp;quot;. WE SAID THAT DAILY PEFR AVERAGE REPRESENTS EVERYDAY CONDITIONS BETTER THAN END-OF-STUDY FEV1. THIS IS FACT, NOT OPINION! NEVERTHELESS THE SENTENCE HAS BEEN MODIFIED AS SUGGESTED.&lt;/p&gt;&lt;p&gt;I like the way that you have included references to the other studies &lt;/p&gt;&lt;p&gt;THANKS&lt;/p&gt;&lt;p&gt;Lung function&lt;br&gt;Please recheck Hansen again 010101 and 010201......SD seems small (weight high). Is there any chance it is the SE (and wrongly labelled in the paper?)&lt;/p&gt;&lt;p&gt;THE SDS HAVE BEEN RECALCULATED AND WERE CORRECT. PLEASE SEE &amp;quot;METHODS OF THE REVIEW-ANALYSIS&amp;quot; FOR A &lt;br&gt;DISCUSSION OF THE PROBLEMS WITH THIS PAPER.  ALL SDS AND DATA EXTRACTION HAVE BEEN RECHECKED AND THEY ARE AND WERE CORRECT.  &lt;/p&gt;&lt;p&gt;Is the FEV1 the change or the final FEV1? If it is a mixture you should probably use SMD.&lt;br&gt;it may be interesting to do a subgroup analysis on type of med-i.e.look at currently used meds &lt;/p&gt;&lt;p&gt;FINAL IS FEV1, NOT A MIXTURE, SUBGROUP SEPARATION IN OUTCOME LAYOUT DONE AS REGARDS MEDICATION FOR POST-BRONCHODILATOR VALUES, OBVIOUSLY THERE IS NO SUBGROUPS FOR PRE-BRONCHODILATOR VALUES.  &lt;/p&gt;&lt;p&gt;Walking test&lt;br&gt;lack of significance is due to the small numbers of patients and large SDs not the small numbers of studies. A minimum clinically important difference is 30 metres (Guyatt). &lt;/p&gt;&lt;p&gt;DON'T TOTALLY AGREE, USED BOTH (SMALL NUMBER AND SIZE) AS REASONS AND REFERENCE ADDED.   &lt;/p&gt;&lt;p&gt;Symptoms:&lt;br&gt;probably shouldn't pool 011401, 011402 011403 to get an overall statistic as 1401 and 1402 contain the same studies (therefore are not independent)i.e. Wilson and Silins. Perhaps just report them separately esp 1403. There are real problem combining symptom scores like this......Paul Jones may have a problem with it. This is especially of concern when the other studies did not show a difference.....the conclusions need to be cautious here.&lt;/p&gt;&lt;p&gt;DONE AND ALL SYMPTOMS SCORES LIKE ALL OTHER DATA RE-EXTRACTED AND ALL RE-CHECKED. WE DON'T HAVE ANY PROBLEMS WITH THE WAY THE DATA HAS BEEN COMBINED AND ARE WILLING TO DISCUSS IT WITH PAUL JONES IF NEED BE.  &lt;/p&gt;&lt;p&gt;Sie effects...did studies report total side effects or any side effects? &lt;/p&gt;&lt;p&gt;NONE REPORTED AT ALL, AS DISCUSSED&lt;/p&gt;&lt;p&gt;Discussion:&lt;/p&gt;&lt;p&gt;Need to mention limitations of meta analysis in cross over studies, metanalysis of symptoms scores&lt;/p&gt;&lt;p&gt;DONE&lt;/p&gt;&lt;p&gt;I think you need to tone down the conclusion in para 3. Even though there are few studies and small numbers of pts this review does show evidence of an effect on lung function, symptoms, pt preference, treatment failure. These effects appear clinically relevant as well as statistically significant. These meds are popular because they work! Agree that we have little data on disease progression, hospitalisation, exacerbation rate, quality of life, mortality&lt;/p&gt;&lt;p&gt;DONE&lt;/p&gt;&lt;p&gt;Para 5 a bit confusing esp lines 3 and 4. Lung function and symptom scores are separate outcomes.&lt;/p&gt;&lt;p&gt;REALISE THAT THE TWO ARE SEPARATE OUTCOMES, RE-DONE.  &lt;/p&gt;&lt;p&gt;Do you want to go into the mechanism why bness may be improved with bronchodilator&lt;/p&gt;&lt;p&gt;THIS HAS BEEN BRIEFLY DISCUSSED.  &lt;/p&gt;&lt;p&gt;Para 6 Walk test -only a few studies, large SDs, can't draw strong conclusions...avoid too much interpretation like &amp;quot;Disappointing&amp;quot; &lt;/p&gt;&lt;p&gt;DONE&lt;/p&gt;&lt;p&gt;Para 7 again.........very strong conclusions.suggest &amp;quot;there was an overwhelming effect in favour of beta agonists in terms of pat pref and dropout rate.........&amp;quot;.&lt;br&gt;para 4 &amp;quot;baseline&amp;quot; confusing&amp;quot; ?prebronchodilator. &lt;/p&gt;&lt;p&gt;CHANGED&lt;/p&gt;&lt;p&gt;I think the last paragraph should go up the top of the discussion! (I need to think a bit about the discussion and implications a bit more-what this review really tells us...these are my first comments...I will probably modify slightly next time as well)&lt;/p&gt;&lt;p&gt;NO, LAST PARAGRAPH IS WHERE IT WAS, BUT OTHERS HAVE BEEN REARRANGED SO IT READS BETTER NOW.  &lt;/p&gt;&lt;p&gt;Really need to make a comment here about side effects.....as this may limit their usefulness, and rule them out for some pts.&lt;/p&gt;&lt;p&gt;DONE, NO SIDE EFFECTS WERE REPORTED, DISCUSSED IN TEXT.&lt;/p&gt;&lt;p&gt;Implications for practice:&lt;br&gt;Regular use of b ag for at least 7 days is associated with an improvement in post bronchodilator lung function, and in symptoms of bness (wheeze data isn't shown in a mean +spread format?). Patients were far more likely to prefer this to placebo, and less likely to fail treatment. However not alI patients will respond. Because there is little evidence that b agonists modify disease progression they should therefore be used only in patients who derive symptomatic benefit. ( Your sentence about N of 1 could go here) . b ags are cheap, readily available, easy to use, and their place as first line agents for COPD is supported by this review. The concern about long term adverse effects on disease progression and exacerbation rates is unable to be addressed in this review&lt;/p&gt;&lt;p&gt;CHANGED BUT MORE ADDDED FOR CLARITY AND &amp;quot;N OF 1&amp;quot; LEFT IN IMPLICATIONS FOR RESEARCH AS IT SEEMS MORE APPROPRIATE HERE THAN ANY WHERE ELSE (THERE ARE NO STUDIES COMPARING IT WITH A MUCH SIMPLER EMPIRICAL TRIAL), FURTHER EXPLANATORY TEXT ADDED.  &lt;/p&gt;&lt;p&gt;Implications for research:&lt;br&gt;Agree about your first sentence...however is is rather unlikely these trials will be done now that there are anticholinergics and Long Acting B agonists. Studies that compare different regimens/combinations/delivery mechanisms may be the best we can hope for. &lt;/p&gt;&lt;p&gt;CHANGED&lt;/p&gt;&lt;p&gt;Characterisitics of included studies&lt;/p&gt;&lt;p&gt;participants...ages?&lt;/p&gt;&lt;p&gt;RE-DONE, AS REVMAN 4.0.4 SELECTIVELY REMOVES TEXT DURING IMPORTING AND EXPORTING THE REVIEW.  &lt;/p&gt;&lt;p&gt;&lt;br&gt;Dullinger-?complete for participants&lt;/p&gt;&lt;p&gt;RE-DONE, AS REVMAN 4.0.4 SELECTIVELY REMOVES TEXT DURING IMPORTING AND EXPORTING THE REVIEW.  &lt;/p&gt;&lt;p&gt;in NOTES here put anything you did e.g. how you calculated SD, wrote for more data....anything odd about the study etc, to remind you.&lt;/p&gt;&lt;p&gt;NOT ADDED HERE BUT PUT IN TEXT AS APPLIES GENERALLY TO STUDIES AND ANY PARTICULAR CASES (E.G HANSEN) DISCUSSED INDIVIDUAL FOR THE READER'S BENEFIT.&lt;/p&gt;" NOTES_MODIFIED="2009-05-26 11:03:44 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" REVIEW_NO="SBA-COP" REVMAN_SUB_VERSION="5.0.20" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2009-05-26 12:04:40 +0200" MODIFIED_BY="Toby Lasserson">
<TITLE>Short-acting beta2-agonists for stable chronic obstructive pulmonary disease</TITLE>
<CONTACT MODIFIED="2009-05-26 12:04:40 +0200" MODIFIED_BY="Toby Lasserson"><PERSON ID="8604" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Piersante</FIRST_NAME><LAST_NAME>Sestini</LAST_NAME><POSITION>Lecturer</POSITION><EMAIL_1>sestini@unisi.it</EMAIL_1><ADDRESS><DEPARTMENT>Institute of Respiratory Diseases</DEPARTMENT><ORGANISATION>University of Siena</ORGANISATION><ADDRESS_1>Viale Bracci 3</ADDRESS_1><ADDRESS_2>53100</ADDRESS_2><CITY>Siena</CITY><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 0577 586794</PHONE_1><PHONE_2>+39 0577 280744</PHONE_2></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2009-05-26 12:04:40 +0200" MODIFIED_BY="Toby Lasserson"><PERSON ID="8604" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Piersante</FIRST_NAME><LAST_NAME>Sestini</LAST_NAME><POSITION>Lecturer</POSITION><EMAIL_1>sestini@unisi.it</EMAIL_1><ADDRESS><DEPARTMENT>Institute of Respiratory Diseases</DEPARTMENT><ORGANISATION>University of Siena</ORGANISATION><ADDRESS_1>Viale Bracci 3</ADDRESS_1><ADDRESS_2>53100</ADDRESS_2><CITY>Siena</CITY><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 0577 586794</PHONE_1><PHONE_2>+39 0577 280744</PHONE_2></ADDRESS></PERSON><PERSON ID="19430" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>E</FIRST_NAME><LAST_NAME>Renzoni</LAST_NAME><ADDRESS><ORGANISATION>Royal Brompton Hospital</ORGANISATION><CITY>London</CITY><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="4948" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Stewart</FIRST_NAME><LAST_NAME>Robinson</LAST_NAME><EMAIL_1>s.robins@auckland.ac.nz</EMAIL_1><ADDRESS><DEPARTMENT>Department of Physiology</DEPARTMENT><ORGANISATION>School of Medicine</ORGANISATION><ADDRESS_1>University of Auckland</ADDRESS_1><ADDRESS_2>Private Bag 92019</ADDRESS_2><CITY>Auckland</CITY><COUNTRY CODE="NZ">New Zealand</COUNTRY></ADDRESS></PERSON><PERSON ID="4917" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Phillippa</FIRST_NAME><LAST_NAME>Poole</LAST_NAME><POSITION>Associate Professor in Medicine FMHS</POSITION><EMAIL_1>p.poole@auckland.ac.nz</EMAIL_1><ADDRESS><ORGANISATION>University of Auckland</ORGANISATION><ADDRESS_1>Private Bag 92019</ADDRESS_1><CITY>Auckland</CITY><COUNTRY CODE="NZ">New Zealand</COUNTRY><PHONE_1>0064-9-373 7599 ext: 86747</PHONE_1><FAX_1>0064-9-373 7555</FAX_1></ADDRESS></PERSON><PERSON ID="19428" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Felix</FIRST_NAME><MIDDLE_INITIALS>SF</MIDDLE_INITIALS><LAST_NAME>Ram</LAST_NAME><POSITION>Senior Lecturer in Respiratory Medicine &amp; Clinical Pharmacology</POSITION><EMAIL_1>fsfram@yahoo.co.uk</EMAIL_1><ADDRESS><DEPARTMENT>School of Health Sciences</DEPARTMENT><ORGANISATION>Massey University - Auckland</ORGANISATION><ADDRESS_1>24 Portsea Place</ADDRESS_1><ADDRESS_2>Chatswood, North Shore</ADDRESS_2><CITY>Auckland</CITY><COUNTRY CODE="NZ">New Zealand</COUNTRY><FAX_1>+64 9 419 6435</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2009-05-26 11:03:44 +0100" MODIFIED_BY="Toby J Lasserson">
<UP_TO_DATE>
<DATE DAY="14" MONTH="5" YEAR="2002"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="4" MONTH="4" YEAR="2002"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2000"/>
</DATES>
<WHATS_NEW NOTES="&lt;p&gt;04/04/2002&lt;br&gt;An update search for studies was conducted in February 2002. However, this failed to identify any new studies fulfilling the criteria for inclusion in the review. Currently more evidence is available on the effectiveness of newer long-acting beta-2 agonists and anticholinergics. Due to their longer duration of action, these compounds may be more practical and/or effective than the short-acting drugs covered in this review. Therefore, the  main conclusions of the review has been changed to reflect the wider choice of effective treatments currently available for improving clinical conditions in patients with COPD.&lt;/p&gt;">
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="22" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="14" MONTH="5" YEAR="2002"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Felix Ram is funded by The Netherlands Astma Fonds</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-08-22 16:25:18 +0100" MODIFIED_BY="Toby J Lasserson">
<SUMMARY MODIFIED="2008-08-22 16:11:10 +0100" MODIFIED_BY="Toby J Lasserson">
<TITLE MODIFIED="2008-08-22 16:11:10 +0100" MODIFIED_BY="Toby J Lasserson">Short-acting beta2-agonists for stable chronic obstructive pulmonary disease</TITLE>
<SUMMARY_BODY>
<P>This review has shown that regular use for at least seven days of inhaled beta-2 medicines that relieve airways obstruction and can also improve the symptoms associated with chronic obstructive pulmonary disease (COPD) in most patients but not all. Patients are far more likely to prefer treatment with these type of medicines than with placebo, and less likely to fail or drop-out from treatment when treated with such medicines. Regular treatment with such inhaled medicines should be reserved for those patients who report symptomatic and clinical benefit from their use. Newer, long acting bronchodilators are currently available, and they may be more practical and/or effective in these patients. However, this review indicates that these older inexpensive drugs are effective in the treatment of COPD.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-08-22 16:10:58 +0100" MODIFIED_BY="Toby J Lasserson">
<ABS_BACKGROUND>
<P>Chronic Obstructive Pulmonary Disease (COPD) is a chronic condition characterised by progressive airflow limitation that is at most partially reversible. Despite the lack of reversibility patients often report symptomatic improvement with short-acting beta-2 bronchodilator medication. Short-acting beta-2 bronchodilators are used in the management of both stable and acute exacerbations of COPD.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the clinical effectiveness and assess the adverse effects of regular treatment with short-acting beta-2 agonists bronchodilators in patients with stable COPD.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>A search was carried out using the Cochrane Airways Group database. In addition, the reference lists of review articles and the randomised controlled trials (RCTs) retrieved in full text were searched for other potentially relevant citations.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>RCTs of at least one week in duration comparing treatment with inhaled short-acting beta-2 agonists with placebo in patients with stable COPD.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-08-22 16:10:12 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Data extraction and study quality assessment was performed independently by two reviewers. Where further or missing data was required, authors of studies were contacted. The data were analysed using the Cochrane Review Manager software. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-08-22 16:10:58 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Thirteen studies were included in this review. All studies used a crossover design and were of high quality. Spirometry performed at the end of the study period and after the administration of treatment (post-bronchodilator) showed a slight but significant increase in FEV1 and FVC when compared to placebo (WMD 0.14 L; 95%CI 0.04, 0.25 &amp; WMD 0.30 L; 95%CI 0.02, 0.58, respectively). In addition, both morning and evening PEFR were significantly better during active treatment than during placebo (WMD 29.17 L/min; 95%CI 0.25, 58.09 &amp; WMD 36.75 L/min; 95%CI 2.56, 70.94, respectively).</P>
<P>A significant improvement in daily breathlessness score was observed during treatment with beta-2 agonist when compared to placebo (SMD 1.33; 95%CI 1.0, 1.65).</P>
<P>The risk of dropping out of the study (treatment failure) when on treatment with placebo was almost twice that of patients on treatment with beta-2 agonists (RR 0.49; 95%CI 0.33, 0.73). Patients preferred beta-2 agonists almost 10 times more frequently to placebo (OR 9.04; 95%CI 4.64, 17.61).</P>
<P>One study that used a validated questionnaire for 'quality of life' assessment, found highly significant improvements in the scores for dyspnoea (p=0.003) and fatigue (p=0.0003) during treatment with salbutamol.</P>
<P>No studies reported serious side effects during treatment with inhaled beta-agonists. However, none of the studies were of sufficient length or size in order to allow any meaningful information on long-term occurrence of side effects.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Use of short-acting beta-2 agonists on a regular basis for at least seven days in stable COPD is associated with improvements in post bronchodilator lung function and a decrease in breathlessness. Patients are far more likely to prefer treatment with beta-2 agonists than placebo, and less likely to drop out from such treatment. None of the studies included in this review reported sufficient data or were of sufficient length or size in order to provide reliable information on adverse effects. Therefore large scale, parallel, longer term studies would be needed to investigate the effect of treatment with regular inhaled beta-2 agonists on mortality, disease progression and side effects. Newer, long acting bronchodilators (including long-acting beta-2 agonists) are currently available and they may be more practical and/or effective in these patients. However, this review indicates that treatment with these older, inexpensive drugs is beneficial in patients with COPD.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-08-22 16:23:08 +0100" MODIFIED_BY="Toby J Lasserson">
<BACKGROUND>
<P>Chronic Obstructive Pulmonary Disease (COPD) is a chronic condition characterised by progressive airflow limitation that is at most partially reversible. Despite the lack of reversibility patients often report symptomatic improvement with short-acting beta-2 bronchodilator medications. These agents are widely used and are recommended for use in management guidelines for COPD (American Thoracic Society; ATS, European Respiratory Society; ERS, British Thoracic Society; BTS, Global Initiative on Chronic Obstructive Lung Disease, GOLD). They are used either on a "as required" or "regular plus as required basis" and may also be used in conjunction with other bronchodilator medicines such as ipratropium and methyl-xanthines. Short-acting beta-2 bronchodilators are used in both the chronic stable management of COPD and in acute exacerbations. Short-acting beta-2 agonist can be delivered in several ways, for example, by metered dose inhaler, dry powder inhaler or by nebulisation.</P>
<P>This review examined the effect of short-acting beta-2 bronchodilators given by inhalation in stable COPD.</P>
</BACKGROUND>
<OBJECTIVES>
<P>(i) To determine the effect of inhaled short-acting beta-2 agonist bronchodilators compared with placebo in stable COPD.<BR/>(ii) To assess the adverse effects of short-acting beta-2 agonist bronchodilators in stable COPD.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-08-22 16:15:52 +0100" MODIFIED_BY="Toby J Lasserson">
<SELECTION_CRITERIA MODIFIED="2008-08-22 16:13:31 +0100" MODIFIED_BY="Toby J Lasserson">
<CRIT_STUDIES>
<P>Only randomised controlled trials were considered for inclusion.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Adults with stable COPD as defined by internationally accepted guidelines (e.g. BTS, ERS, ATS).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>At least seven days of regular treatment with short-acting beta-2 bronchodilators given by inhalation compared with placebo. Short-acting beta-2 bronchodilators include salbutamol (albuterol), fenoterol, terbutaline, bitolterol, pirbuterol, reproterol and metaproterenol (orciprenaline). Data from trials where beta-2 agonists were used alone or in combination with other medicines (e.g. ipratropium bromide) were used only if there was direct comparison between the beta-2 agonist bronchodilator and placebo alone.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-08-22 16:13:31 +0100" MODIFIED_BY="Toby J Lasserson">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-08-22 16:13:23 +0100" MODIFIED_BY="Toby J Lasserson">
<OL>
<LI>Symptom scores including dyspnoea at rest, dyspnoea on exertion, sputum, cough</LI>
<LI>Quality of life using validated health status questionnaire</LI>
<LI>Lung function measured by forced expiratory volume in 1 second (FEV1), peak expiratory flow rate (PEFR), forced vital capacity (FVC), airway resistance, etc</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-08-22 16:13:28 +0100" MODIFIED_BY="Toby J Lasserson">
<OL>
<LI>Patient preference for active treatment or placebo</LI>
<LI>Number and type of adverse effects</LI>
<LI>Number of study withdrawals</LI>
<LI>Mortality</LI>
<LI>Exercise capacity as assessed by timed or incremental exercise test</LI>
<LI>Days sick as assessed by hospital admissions, or frequency and severity of exacerbations</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>RCTs were identified (without any language restrictions) using the Cochrane Airways Group database. This database was searched using the following terms:</P>
<P>salbutamol OR albuterol OR terbutaline OR isoproterenol OR reproterol OR fenoterol OR orciprenaline OR metaproterenol OR ((beta* AND agonist*) AND short)) OR (bronchodilator* AND short)</P>
<P>In addition, the reference lists of review articles and RCTs retrieved in full were searched for other potentially relevant citations.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-08-22 16:15:52 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDY_SELECTION MODIFIED="2008-08-22 16:14:10 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Abstracts of articles identified using the above search strategy were viewed, and articles that appeared to fulfil the inclusion criteria were retrieved in full. Acute studies (i.e. studies investigating the effect of a single dose of medication) were excluded. From the full text of the remaining articles, two reviewers independently established whether each study met the inclusion criteria as a randomised placebo controlled trial of regular short-acting beta-2 agonist in stable COPD for at least seven days. The percentage agreement was recorded and disagreement was resolved by discussion between the two reviewers. Where there was uncertainty study authors were contacted to clarify the data and or the randomisation method.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-08-22 16:14:07 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Data were extracted onto data extraction sheets (Microsoft Excel) then entered into RevMan 4.1. Each entry was double-checked by both reviewers.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-08-22 16:14:27 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Study quality was assessed using the Cochrane Collaboration approach to assessment of allocation concealment, all trials were scored and entered using the following principles:</P>
<P>Grade A: adequate concealment<BR/>Grade B: uncertain<BR/>Grade C: clearly inadequate concealment<BR/>Grade D: not used (no attempt at concealment)</P>
</QUALITY_ASSESSMENT>
<UNIT_OF_ANALYSIS MODIFIED="2008-08-22 16:15:24 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Despite the fact that all the studies followed a crossover design, only one of them (<LINK REF="STD-Hansen-1994" TYPE="STUDY">Hansen 1994</LINK>) presented 95% CI of the difference computed using paired statistics. We therefore analysed all the studies as if they were parallel studies, entering the SD of treatment and placebo periods as separate groups. For the study by <LINK REF="STD-Hansen-1994" TYPE="STUDY">Hansen 1994</LINK>, we computed an estimate of the SD for placebo and treatment group from the given 95% CI of the difference assuming i) equal variances for the two treatments and ii) a positive correlation coefficient of 0.75 between the response to treatment and placebo (<LINK REF="REF-Cleophas-1996a" TYPE="REFERENCE">Cleophas 1996a</LINK>). The latter assumption was justified by the fact that changes after either treatment were usually small as compared to baseline values and by the observation that COPD patients responsive to terbutaline may also respond to "placebo" (saline) nebulisation (<LINK REF="REF-Poole-1998" TYPE="REFERENCE">Poole 1998</LINK>). Accordingly, the SD of each sample was estimated as the 95% CI of the difference divided by (2*1.96) * sqrt(N). This is because the variance of the difference var(a-b)= (var(a)+var(b))* (1-r), if var(a)=var(b) and r=0.75 then var (a)=var(a-b)/(2*0.25)=2*var(a-b).</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2008-08-22 16:15:52 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Where studies only reported means without any measure for error we estimated the missing standard deviation (SD) by taking an average of the SD's from other studies for that particular outcome. Furthermore we carried out sensitivity analysis (without the study with the estimated SD) in order to observe if the overall result differed significantly. In all cases where this was done the overall result was not different with or without the estimated SD. Outcomes for which SD was estimated as an average of other SD's were FEV1: <LINK REF="STD-Shah-1983" TYPE="STUDY">Shah 1983</LINK>, FVC: <LINK REF="STD-Shah-1983" TYPE="STUDY">Shah 1983</LINK> and PEFR: <LINK REF="STD-Guyatt-1987" TYPE="STUDY">Guyatt 1987</LINK>.</P>
<P>All missing data have been requested by writing to authors but to date we have received no replies. Any data or replies received from our correspondence will be included in any future updates of this review.</P>
</MISSING_DATA>
<DATA_SYNTHESIS MODIFIED="2008-08-22 16:14:43 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Only RCTs were included in the analysis. Data were analysed as either continuous or dichotomous outcomes, using standard statistical techniques:</P>
<P>i) For continuous outcomes, the weighted mean difference (WMD) or the standardised mean difference (SMD) and 95% confidence intervals were calculated.<BR/>ii) For dichotomous outcomes, the relative risk (RR) or odds ratio (OR) was calculated with 95% confidence intervals.</P>
<P>Tests for heterogeneity was not significant for any of the outcomes, therefore sensitivity analysis was not performed. If significant heterogeneity, not explained by study quality had been found, the following sub-group analyses would have been performed:</P>
<P>1. Type of beta-2 agonist<BR/>2. Dose and delivery system (e.g. MDI/nebuliser)<BR/>3. Study duration<BR/>4. Severity of COPD (by baseline lung function)<BR/>5. Setting of study<BR/>6. Age of patients<BR/>7. Concomitant medication</P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-08-22 16:23:08 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDY_DESCRIPTION MODIFIED="2008-08-22 16:16:32 +0100" MODIFIED_BY="Toby J Lasserson">
<SEARCH_RESULTS MODIFIED="2008-08-22 16:16:19 +0100" MODIFIED_BY="Toby J Lasserson">
<P>An update search was conducted in February 2002, which led to the identification of 194 abstracts. However, none fulfilled the criteria for inclusion in the review. Only one study included regular treatment with inhaled short-acting beta-2 agonist in patients with stable COPD compared to placebo (<LINK REF="STD-Cook-2001" TYPE="STUDY">Cook 2001</LINK>). This study was excluded as both study arms included chronic treatment with ipratropium bromide, making it incompatible with previously included studies in the review. Furthermore, as-needed inhaled salbutamol was freely available to all patients, this being one of the outcomes of the review. As a result there was a substantial intake of short-acting beta-2 agonist in the placebo group in this study (<LINK REF="STD-Cook-2001" TYPE="STUDY">Cook 2001</LINK>) which further favours its exclusion.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2008-08-22 16:16:25 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Our analysis was restricted to randomised controlled trials of adults with stable COPD and at least seven days of regular treatment with short-acting beta-2 bronchodilators given by inhalation and compared with placebo. The bibliographic search yielded 391 references. Of these 298 were identified by the title and abstract alone to involve diseases different from COPD (mostly asthma or bronchiolitis) or were studies that used oral rather than inhaled beta-2 agonists or were studies in patients during acute exacerbations. The full text of the remaining 93 papers were obtained and examined, together with another seven papers identified from the reference list of these full papers and also five papers known by the reviewers. Out of a total of 105 papers 56 were found to report the effects of chronic treatment with inhaled beta-2 agonists in patients with stable COPD. Of these, 43 were excluded, mostly because of the lack of a comparative placebo group, except in two cases where beta agonists were administered exclusively or in combination with other drugs. Thirteen studies were eventually included in this review. Four of the included studies (<LINK REF="STD-Guyatt-1987" TYPE="STUDY">Guyatt 1987</LINK>,<LINK REF="STD-Guyatt-1988" TYPE="STUDY">Guyatt 1988</LINK>,<LINK REF="STD-Guyatt-1989" TYPE="STUDY">Guyatt 1989</LINK> &amp; <LINK REF="STD-Jaeschke-1991" TYPE="STUDY">Jaeschke 1991</LINK>) were reports related to the same cohort of patients. Therefore, only one of these studies could be included in each analysis. The treatments consisted of isoproterenol in three studies (<LINK REF="STD-Dullinger-1986" TYPE="STUDY">Dullinger 1986</LINK>, <LINK REF="STD-Klock-1975" TYPE="STUDY">Klock 1975</LINK> &amp; <LINK REF="STD-Light-1975" TYPE="STUDY">Light 1975</LINK>) terbutaline in three (<LINK REF="STD-Hansen-1990" TYPE="STUDY">Hansen 1990</LINK>, <LINK REF="STD-Silins-1985" TYPE="STUDY">Silins 1985</LINK> &amp; <LINK REF="STD-Tandon-1990" TYPE="STUDY">Tandon 1990</LINK>) and salbutamol in the others. Four studies used nebulisers (<LINK REF="STD-Hansen-1990" TYPE="STUDY">Hansen 1990</LINK>, <LINK REF="STD-Light-1975" TYPE="STUDY">Light 1975</LINK>, <LINK REF="STD-Silins-1985" TYPE="STUDY">Silins 1985</LINK> &amp; <LINK REF="STD-Wilson-1980" TYPE="STUDY">Wilson 1980</LINK>) while the others used pressurised metered dose inhalers or other portable hand-held inhaler devices. Patients were exclusively or mostly males in all studies except in <LINK REF="STD-Hansen-1990" TYPE="STUDY">Hansen 1990</LINK>, where 50% of the patients were females. Further details on the included studies can be found in the table for "Characteristics of Included Studies" and also in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>, under "Additional tables."</P>
</INCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Two reviewers independently assessed all potential trials for inclusion. Each reviewer independently applied written inclusion/exclusion criteria to each potential trial to determine the adequacy of patient randomisation, blinding, baseline comparability, outcome measures and the handling of withdrawals/dropouts. Occasional disagreement between reviewers was resolved through open discussion. Complete agreement was reached between the reviewers on all topics. All included studies were of high quality, randomised, double blind and of crossover design. Most of the studies had small sample size and some used very short-acting, outdated compounds. One study (<LINK REF="STD-Shah-1983" TYPE="STUDY">Shah 1983</LINK>) failed to provide statistical figures except for mean and range. Standard deviation for the 6 minute walking distance in this study was extracted from data presented in a figure. Despite the fact that all the studies followed a crossover design, only one of them (<LINK REF="STD-Hansen-1994" TYPE="STUDY">Hansen 1994</LINK>) presented 95% CI of the difference computed using paired statistics. We therefore analysed all the studies as if they were parallel studies, entering the SD of treatment and placebo periods as separate groups.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-08-22 16:23:08 +0100" MODIFIED_BY="Toby J Lasserson">
<SUBSECTION>
<HEADING LEVEL="5">SPIROMETRY</HEADING>
<P>Although spirometry was carried out before the start of the treatment period (baseline spirometry) in all studies, data were not reported by most studies. Furthermore, the time at which spirometry was measured after the last bronchodilator dose varied greatly and was not recorded in some studies. Spirometry done at the end of the treatment period and before beta-2 agonist (pre-bronchodilator) showed no significant difference in any of the studies for FEV1 (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) or FVC (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). When spirometry was performed after administration of beta-2 agonist (post-bronchodilator) at the end of the treatment period both FEV1 (WMD 0.140 L, 95%CI 0.04, 0.25, <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>) and FVC (WMD 0.30 L, 95%CI 0.02, 0.58, <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>) improved slightly but significantly when compared to placebo.</P>
<P>Not many studies measured FRC, TLC or RV at the end of the study period and those that did made these measurements several hours after treatment. These showed no significant difference ( p&gt;0.05 in all cases) between the bronchodilator and placebo groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">PEAK FLOW RATE</HEADING>
<P>Unlike spirometry which is usually measured only at the end of treatment period, PEFR can be recorded daily, usually both in the morning and evening, and therefore represents the overall condition of the patient during the study period, rather than at a single time point. Post-bronchodilator morning PEFR was significantly higher in the treatment group than in the placebo group (WMD 29.17 L/min; 95%CI 0.25, 58.09, <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). Post-bronchodilator evening PEFR was also significantly higher in the treatment group (WMD 36.75 L/min; 95%CI 2.56, 70.94, <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>). In addition to the studies included in the meta-analysis, <LINK REF="STD-Hansen-1990" TYPE="STUDY">Hansen 1990</LINK> also reported a significant increase (p=0.0001) in PEFR during active treatment as opposed to placebo (11% &amp; 5% in the morning and 8% &amp; 3% in the evening, respectively). <LINK REF="STD-Shah-1983" TYPE="STUDY">Shah 1983</LINK> also reported a "significant increase" in mean daily PEFR from 157 L/min during placebo to 182 L/min while on salbutamol, using a signed rank test. As previously observed for spirometry no significant differences were noted when PEFR was recorded before bronchodilator therapy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">BREATHLESSNESS</HEADING>
<P>Breathlessness was measured on various scales, therefore studies that presented data in a suitable form (<LINK REF="STD-Silins-1985" TYPE="STUDY">Silins 1985</LINK>, <LINK REF="STD-Wilson-1980" TYPE="STUDY">Wilson 1980</LINK>, <LINK REF="STD-Dullinger-1986" TYPE="STUDY">Dullinger 1986</LINK>, <LINK REF="STD-Guyatt-1989" TYPE="STUDY">Guyatt 1989</LINK>, <LINK REF="STD-Hansen-1990" TYPE="STUDY">Hansen 1990</LINK> &amp; <LINK REF="STD-Shah-1983" TYPE="STUDY">Shah 1983</LINK>) were combined using standardised mean differences (SMD). A highly significant improvement in daily breathlessness score was observed during treatment with beta-2 agonist (SMD 1.33; 95%CI 1.01, 1.65, <LINK REF="CMP-001.19" TYPE="ANALYSIS">Analysis 1.19</LINK>). Morning and evening breathlessness scores did not change significantly after treatment with beta-2 agonist. Studies that failed to present their data for breathlessness in a suitable form for inclusion in the analysis reported no difference in dyspnea scores between active treatment and placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">WHEEZE</HEADING>
<P>Three studies (<LINK REF="STD-Klock-1975" TYPE="STUDY">Klock 1975</LINK>, <LINK REF="STD-Light-1975" TYPE="STUDY">Light 1975</LINK> &amp; <LINK REF="STD-Wilson-1980" TYPE="STUDY">Wilson 1980</LINK>) did show an improvement in "wheeze" during treatment with salbutamol, whereas no difference was reported in one (<LINK REF="STD-Silins-1985" TYPE="STUDY">Silins 1985</LINK>). Unfortunately, it was impossible to combine these data for meta-analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">COUGH</HEADING>
<P>Data from only one study (<LINK REF="STD-Silins-1985" TYPE="STUDY">Silins 1985</LINK>) was in a suitable format for inclusion in the analysis, which did not show any significant difference between treatment and placebo groups. There were two further studies for which data was not reported in a suitable format for inclusion in the analysis, one (<LINK REF="STD-Klock-1975" TYPE="STUDY">Klock 1975</LINK>) showed that cough improved significantly during treatment with beta-2 agonist while the other (<LINK REF="STD-Taylor-1985" TYPE="STUDY">Taylor 1985</LINK>) did not show any improvement in cough.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">SPUTUM PRODUCTION</HEADING>
<P>Two studies (<LINK REF="STD-Wilson-1980" TYPE="STUDY">Wilson 1980</LINK> &amp; <LINK REF="STD-Silins-1985" TYPE="STUDY">Silins 1985</LINK>) reported this outcome that showed no significant difference in sputum production between the beta-2 agonist and placebo groups. Three other studies (<LINK REF="STD-Klock-1975" TYPE="STUDY">Klock 1975</LINK>, <LINK REF="STD-Light-1975" TYPE="STUDY">Light 1975</LINK> &amp; <LINK REF="STD-Taylor-1985" TYPE="STUDY">Taylor 1985</LINK>) for which the data was not published in a usable format also reported no changes in sputum production.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">TREATMENT FAILURES/EXACERBATIONS (DROP-OUTS)</HEADING>
<P>Five trials (<LINK REF="STD-Guyatt-1987" TYPE="STUDY">Guyatt 1987</LINK>, <LINK REF="STD-Silins-1985" TYPE="STUDY">Silins 1985</LINK>, <LINK REF="STD-Tandon-1990" TYPE="STUDY">Tandon 1990</LINK>, <LINK REF="STD-Taylor-1985" TYPE="STUDY">Taylor 1985</LINK> &amp; <LINK REF="STD-Wilson-1980" TYPE="STUDY">Wilson 1980</LINK>) reported the number of patients who dropped out from their study because of an exacerbation of dyspnoea during treatment with beta-2 agonist or placebo (treatment failure). Half as many patients dropped out of the beta-2 agonist group as from the placebo group (22 versus 46). The risk of treatment failure was significantly greater in the placebo group than in the beta-2 agonist group (RR 0.49; 95%CI 0.33, 0.73, <LINK REF="CMP-001.20" TYPE="ANALYSIS">Analysis 1.20</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">PATIENT PREFERENCE</HEADING>
<P>Four studies (<LINK REF="STD-Hansen-1990" TYPE="STUDY">Hansen 1990</LINK>, <LINK REF="STD-Light-1975" TYPE="STUDY">Light 1975</LINK>, <LINK REF="STD-Silins-1985" TYPE="STUDY">Silins 1985</LINK> &amp; <LINK REF="STD-Wilson-1980" TYPE="STUDY">Wilson 1980</LINK>) reported patient preference which showed that patients were almost 10 times more likely to prefer beta-2 agonist than placebo (OR 9.04; 95%CI 4.64, 17.61). Furthermore, in one study (<LINK REF="STD-Taylor-1985" TYPE="STUDY">Taylor 1985</LINK>) for which the data was not reported in a usable format, patients ranked treatment with salbutamol better than placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">QUALITY OF LIFE</HEADING>
<P>Data for this outcome were not reported in a usable format for inclusion into the review but one study (<LINK REF="STD-Dullinger-1986" TYPE="STUDY">Dullinger 1986</LINK>) reported non-significant increases in the Oxygen Cost Diagram from 51.3 (95%CI 25.3, 86.2) during placebo to 57.7 (95%CI 32.3, 88.3) when metaproterenol was used. Using the Chronic Respiratory Disease Questionnaire (CRQ), <LINK REF="STD-Guyatt-1989" TYPE="STUDY">Guyatt 1989</LINK> reported highly significant improvements during salbutamol treatment in the scores of the domains for dyspnoea (p=0.003) and fatigue (p=0.0003).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">WALKING TEST</HEADING>
<P>Four studies reported on the effect of beta-2 agonist on either the 6MW or 12MW distance. Clinically and statistically significant increases in 6MW distance was reported in two studies (<LINK REF="STD-Guyatt-1987" TYPE="STUDY">Guyatt 1987</LINK>: 42 metres with p&lt;0.018 &amp; <LINK REF="STD-Shah-1983" TYPE="STUDY">Shah 1983</LINK>: 35 metres with p&lt;0.05), one study (<LINK REF="STD-Hansen-1990" TYPE="STUDY">Hansen 1990</LINK>) showed a (non-significant) decrease of 2 metres in 6MW distance. The study by <LINK REF="STD-Dullinger-1986" TYPE="STUDY">Dullinger 1986</LINK> showed an increase of 38 metres in 12MW distance, which did not reach significance. Due to the small sample size, small number of studies, large SDs and the fact that the <LINK REF="STD-Hansen-1990" TYPE="STUDY">Hansen 1990</LINK> et al study reported a negative result, was larger than the others and therefore carried more weight in the meta analysis, no significant differences were found in overall walking distance between the bronchodilator and the placebo groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">BETA-2 USAGE (RESCUE MEDICATION USAGE)</HEADING>
<P>Three studies (<LINK REF="STD-Wilson-1980" TYPE="STUDY">Wilson 1980</LINK>, <LINK REF="STD-Silins-1985" TYPE="STUDY">Silins 1985</LINK> &amp; <LINK REF="STD-Hansen-1990" TYPE="STUDY">Hansen 1990</LINK>) reported non-significant reductions in the use of rescue bronchodilators during treatment with beta-2 agonist. Only the former two studies presented data in a form suitable for inclusion in the analysis. Due to the small number of studies and the low number of patients in these two studies the difference between beta-2 agonist and placebo treatment failed to reach statistical significance.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">SIDE EFFECTS</HEADING>
<P>No studies reported serious side effects during treatment with inhaled beta-agonists. However, none of the studies had sufficient patient numbers or length of observation in order to reasonably exclude any possible side effects.</P>
<P>The following outcomes reported by only one study showed no significant difference (p&gt;0.05) between the beta-2 agonist and placebo groups: progressive cycle ergometry, PaO2, SGaw and Raw. None of the studies reported data on hospital admissions, exacerbation rates or mortality.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Despite the great number of COPD patients currently being treated with beta-2 agonist bronchodilators, we found very few studies suitable for inclusion in our review. Most of the studies were small with less than 24 subjects. Since some of the included studies were old and therefore used very short acting and outdated compounds (e.g. isoproterenol). Data from these studies should be combined with caution with those of the more active compounds (e.g. salbutamol, terbutaline) which are widely used in current clinical practice.</P>
<P>The small number of studies found for this review suggests that short-acting beta-2 agonists have gained popularity in the treatment of stable COPD from the results of acute studies and from uncontrolled clinical trials, as well as from a perception of benefit by patients. </P>
<P>More studies exist in which treatment with inhaled short-acting beta-2 agonists is compared with other active treatments, such as anticholinergics or theophylline alone or in combination. Unfortunately because of the lack of placebo arms these studies had to be excluded from our analysis. Some of these comparisons will be addressed in other Cochrane reviews. Due to the small number and size of controlled trials, it is difficult to evaluate the real benefit or possible side effects afforded by short-acting beta-2 agonists in COPD. Nevertheless our analysis shows significant and sustained improvements in respiratory function parameters and symptoms of dyspnoea as discussed below, while data on long term outcomes (such as hospital admissions, side effects, and survival) are lacking.</P>
<P>Although we restricted our analysis to typical COPD patients (as defined by the ATS criteria) and excluded studies that used patients with asthma, study populations varied slightly in severity (from moderate obstruction to severe respiratory disability), in acute bronchodilator response to beta-2 agonists and with patients acutely responding or not responding to bronchodilators who were alternatively selected or excluded in different studies. Despite these differences, results were fairly consistent across different studies. Therefore, the results of this review should be applicable to most patients with COPD, possibly excluding those with mild COPD or with characteristics of asthma. </P>
<P>Unlike pre-bronchodilator respiratory function, FEV1 measured post-bronchodilator was found to be slightly (140 ml) but significantly (p=0.008) improved after active treatment as opposed to placebo. This observation confirms the bronchodilator effect of beta-2 agonist treatment in COPD observed in several acute studies (<LINK REF="REF-Formgren-1994" TYPE="REFERENCE">Formgren 1994</LINK>, <LINK REF="REF-Ikeda-1999" TYPE="REFERENCE">Ikeda 1999</LINK>, <LINK REF="REF-Iversen-1999" TYPE="REFERENCE">Iversen 1999</LINK>, <LINK REF="REF-Mutterlein-1990" TYPE="REFERENCE">Mutterlein 1990</LINK>). None of the included studies were designed to investigate changes in the bronchodilator activity over time and our data shows no evidence for the hypothesis that this activity is attenuated by chronic treatment with inhaled short-acting beta-2 agonists. The short duration of the included studies in this review made them unsuitable for evaluating any effect on disease progression over time. </P>
<P>Analysis of PEFR data confirms that the improvement of respiratory function after beta-2 agonists persist during the day and throughout the treatment period. Similarly, the improvement in daily breathlessness scores indicates that most patients with COPD gain significant benefit from inhaled beta-2 agonists throughout treatment. Although we were forced to combine breathlessness scores using standardised means to overcome the different scales used in the included studies, it should be noted that the improvement in the score was consistent across the many different studies. Therefore, although the size of the improvement cannot be exactly estimated using this combined score this effect is likely to be clinically significant. Breathlessness in COPD, especially during exercise, originates from a variety of factors, including muscular, cardiovascular, metabolic, gas exchange and pulmonary mechanism dysfunction. Among these, the main respiratory cause of breathlessness appears to be dynamic hyperinflation caused by the presence of severe flow limitation during expiration. This expiratory flow limitation promotes pulmonary hyperinflation by prolonging the time required for the respiratory system to reach its relaxed volume during expiration. In the presence of expiratory flow limitation any increase in expiratory flow can only be accomplished by raising the end-expiratory lung volume and allowing tidal breathing to occur at a higher absolute lung volume. This mechanism however leads to increments in dynamic hyperinflation thus increasing inspiratory threshold load on the respiratory muscles resulting in dyspnoea. Bronchodilators work by allowing expiratory flow limitation to occur at a lower absolute lung volume thus decreasing dynamic hyperinflation and dyspnoea (<LINK REF="REF-Tantucci-1999" TYPE="REFERENCE">Tantucci 1999</LINK>). In COPD, parameters of inspiratory function (such as Inspiratory Capacity or Peak Inspiratory Flow) are known to correlate better with both hyperinflation and dyspnoea (<LINK REF="REF-Bellamy-1981" TYPE="REFERENCE">Bellamy 1981</LINK>, <LINK REF="REF-Connellan-1982" TYPE="REFERENCE">Connellan 1982</LINK>, <LINK REF="REF-Noseda-1995" TYPE="REFERENCE">Noseda 1995</LINK> &amp; <LINK REF="REF-Murariu--1998" TYPE="REFERENCE">Murariu 1998</LINK>) than expiratory parameters. Among the studies included in this review, only <LINK REF="STD-Jaeschke-1991" TYPE="STUDY">Jaeschke 1991</LINK> included a parameter of inspiratory function, Maximal Inspiratory Pressure (MIP). They found that MIP increased after salbutamol (although the increase was only marginally significant), and that this increase was correlated with changes in dyspnoea score also after adjusting for changes in FEV1. In this review it was interesting to note that dyspnoea and wheezing were affected more by treatment with beta-2 agonists than cough and sputum production, which are the clinical hallmarks of this disease. </P>
<P>The walking test is considered to reproduce real-life situation in order to document the benefit of treatment on daily activity in patients. It may be therefore surprising that the studies failed to consistently show an improvement in walking distance after beta-2 agonist with respect to placebo, despite an improvement in respiratory function and symptom scores. This was probably due to the small number and size of studies reporting this outcome, along with the varying responses from the patient population. Furthermore, respiratory conditions are not the only factor influencing the performance of walking distance, which is also affected by several psychological, physical and environmental conditions. In most of these trials the walking test after beta-2 agonist or placebo was performed at least one or more weeks apart, therefore it is possible that an effect of the drug on respiratory function was concealed by changes in some of these other factors. Nevertheless, in two of the three papers (<LINK REF="STD-Guyatt-1987" TYPE="STUDY">Guyatt 1987</LINK> &amp; <LINK REF="STD-Shah-1983" TYPE="STUDY">Shah 1983</LINK>) reporting the results of the 6MW test, an increase in the mean distance walked (42m &amp; 35m, respectively) was noted. Such mean increases can be considered important, since it has been shown that an increase of at least 30 meters in distance walked is of clinical significance (<LINK REF="STD-Guyatt-1987" TYPE="STUDY">Guyatt 1987</LINK>, <LINK REF="REF-Redelmeier-1997" TYPE="REFERENCE">Redelmeier 1997</LINK>).</P>
<P>Patient preference and dropout rate (treatment failure) favoured beta-2 agonist treatment in our meta-analysis. However, one should be suspicious that patient selection could have biased the results of some of these trials. For instance, most of the patients in the studies by <LINK REF="STD-Wilson-1980" TYPE="STUDY">Wilson 1980</LINK> and <LINK REF="STD-Silins-1985" TYPE="STUDY">Silins 1985</LINK> were already on chronic treatment with nebulised bronchodilators, which would make these patients unlikely not to respond to this treatment. It is not surprising that these patients had greater preference for active treatment and more dropouts during placebo. In contrast, in the study by <LINK REF="STD-Hansen-1990" TYPE="STUDY">Hansen 1990</LINK> that excluded patients who had prior treatment with a nebuliser at home showed that 23 patients preferred terbutaline, 3 preferred placebo, 6 preferred the run-in period and the remaining 16 had no preference. Although it is clear that in this study active treatment was superior to placebo, it was surprising to see that only 23/48 patients (less than 50%) preferred terbutaline. </P>
<P>
<LINK REF="STD-Guyatt-1988" TYPE="STUDY">Guyatt 1988</LINK> used an improvement in the physical function domain of the CRQ questionnaire, rather than patient preference, to identify responders and non-responders to bronchodilator therapy. They found that only 14/24 patients responded to salbutamol treatment. Six out of 8 responders showed an increase in FEV1 of greater than 25% after a single dose of beta-2 agonist, 6/11 showed an increase in FEV1 between 15 to 25% and 2/5 showed an increase of less than 15%. Although patients with better bronchodilator response are somewhat more likely to have symptomatic benefit from long-term therapy, lack of acute bronchodilation does not preclude a clinical response. Using different protocols, <LINK REF="STD-O_x0027_Driscoll-1990" TYPE="STUDY">O'Driscoll 1990</LINK>, <LINK REF="STD-Teale-1991" TYPE="STUDY">Teale 1991</LINK> and <LINK REF="STD-Morrison-1992" TYPE="STUDY">Morrison 1992</LINK> confirmed that only a small proportion of patients with COPD benefited from chronic treatment with bronchodilators and that the response in these patients could not be predicted by the acute response to salbutamol. Guyatt proposed that an "N of 1" study (a double blind study of the effect of treatment or placebo in individual patients) could be performed in each patient and the results from this "N of 1" study used to decide on further treatment on an individual basis (<LINK REF="REF-Guyatt-1986" TYPE="REFERENCE">Guyatt 1986</LINK>). However it is not known whether the results obtained with this approach has been compared with other strategies. </P>
<P>A possible pitfall of crossover studies, such as those found for our analysis, is the presence of carry-over effects of the first treatment into the second treatment period, leading to an underestimation of the real difference among treatments (<LINK REF="REF-Cleophas-1993" TYPE="REFERENCE">Cleophas 1993</LINK>). However, in the available studies, chronic treatment with short-acting beta-2 agonists did not seem to alter pre-bronchodilator respiratory function, suggesting that carry-over effects are unlikely to have occurred in these studies, despite their cross-over design and since most studies had a washout period. </P>
<P>A second possible pitfall associated with crossover designs is that we were forced to analyse crossover studies as if they were parallel studies. It is known (<LINK REF="REF-Cleophas-1996b" TYPE="REFERENCE">Cleophas 1996b</LINK>) that the two methods give identical results if the response to the two treatments in the same individual is completely unrelated, but parallel analysis may lead to decreased statistical power when compared to paired analysis, if the response to the two treatments is positively correlated (i.e. if patients improving during bronchodilator are also more likely to improve somewhat during placebo). This possibility cannot be discarded in our review, since patients responsive to terbutaline have been reported to improve also after "placebo" (saline) nebulisation (<LINK REF="REF-Poole-1998" TYPE="REFERENCE">Poole 1998</LINK>). On the other hand, in our review only four studies used nebulised saline as placebo, and the increased rate of exacerbation during placebo suggests that many patients responsive to bronchodilators actually worsened rather than improve during placebo. This would result in a negative correlation between the responses to the two treatments, and in an increased statistical power of parallel versus paired analysis (<LINK REF="REF-Cleophas-1996a" TYPE="REFERENCE">Cleophas 1996a</LINK> &amp; <LINK REF="REF-Cleophas-1996b" TYPE="REFERENCE">Cleophas 1996b</LINK>). Unfortunately, none of the studies reported the correlation between the responses to the two treatments, and we cannot exclude that our analysis underestimated the statistical significance of the observed differences, as compared to a paired analysis. </P>
<P>Finally, this review did not include comparison with alternative treatments, such as long-acting beta-2 agonist, anti-cholinergic, or combinations of beta-2 agonist and anti-cholinergic and beta-2 agonist drugs. Several recent clinical trials indicate that chronic treatment with inhaled long-acting beta-2 agonists, such as salmeterol or formoterol, is effective in improving clinical conditions and quality of life in COPD (<LINK REF="REF-Appleton-2000" TYPE="REFERENCE">Appleton 2000</LINK>). Due to their longer action, these drugs may provide better coverage over day and night-time, and therefore may prove more effective than the short acting drugs considered in this review. Furthermore, a recent well-controlled trial indicates that chronic inhaled treatment with both ipratropium bromide and salbutamol is no more effective than treatment with chronic ipratropium bromide alone plus inhaled salbutamol on an as-needed basis (<LINK REF="STD-Cook-2001" TYPE="STUDY">Cook 2001</LINK>). Therefore, it can be concluded that several effective treatments are currently available, and while a direct comparison between all of them is not available, a choice can be made on the basis of individual response, preferences, and economical convenience or constraints.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Short acting beta-2 agonists used on a regular basis for at least seven days or more in patients with moderate to severe COPD is associated with an improvement in post bronchodilator lung function and a decrease in symptoms of breathlessness. Patients are far more likely to prefer treatment with beta-2 agonist than placebo, and less likely to fail or dropout from treatment. However, not all patients will respond to treatment with regular beta-2 agonists. The bronchodilator response (or lack of it) after a single administration is a poor predictor of long term clinical response. Since there is little evidence that beta-2 agonists modify disease progression and due to the lack of longer-term data on side effects, beta-2 agonists should therefore be used only in patients who derive symptomatic benefit after a trial period. An on-demand regimen may be more appropriate in other groups of patients, although this question was not specifically addressed in this review. There was no evidence in this review of an increase of adverse effects, however the numbers of patients were small and follow-up was equally short. Newer, longer acting bronchodilators are currently available and they may be more practical and/or effective than the short-acting drugs covered in this review. However, the available evidence indicates that chronic treatment with inexpensive short-acting beta-2 agonist bronchodilators is effective in improving several clinical parameters in patients with COPD.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Large, parallel, long term studies are needed in order to investigate the effect of chronic inhaled beta-2 agonists, possibly in comparison with anticholinergics, on the frequency of exacerbations, occurrence of side effects and any possible effect on the progression of the disease, both in patients with or without a clinical response to acute bronchodilator treatment. As a result of the introduction of long-acting beta-2 agonist, studies are more likely to be conducted using these agents. Therefore, it is unlikely that studies would be performed with short-acting beta-2 agonists versus placebo except possibly in very mild disease. A randomised comparison of bronchodilators given either in an empirical treatment trial with clearly defined outcome measures versus a formal "N of 1" study could be useful in order to devise a more effective and practical strategy for the identification of responders and non responders to beta-2 bronchodilator therapy.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-08-22 16:25:18 +0100" MODIFIED_BY="Toby J Lasserson">
<P>The authors are indebted to the following people: Annibale Biggeri (Department of Statistics, University of Florence) for statistical advice. Anna Bara, Karen Blackhall, Jane Dennis and Steve Milan for continued support, literature searches and providing full text papers; Professor Paul Jones for his help and input as the co-ordinating editor of Cochrane Airways Group, St. George's Hospital, London. We acknowledge the contribution of Felix Ram who was an author on the original version of this review. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>There are no known conflicts of interest.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-08-22 16:24:54 +0100" MODIFIED_BY="Toby J Lasserson">
<P>PS and FR (previous author) carried out all of the work for this review with help from the following people at various stages: ER who help screen and double check abstracts and papers for inclusion, SR who help write up the manuscript, and PP for her comments as the CAG editor.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-08-22 16:16:28 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Dullinger-1986" NAME="Dullinger 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dullinger D, Kronenberg R, Niewoehner DE</AU>
<TI>Efficacy of inhaled metaproterenol and orally-administered theophylline in patients with chronic airflow obstruction</TI>
<SO>Chest</SO>
<YR>1986</YR>
<VL>89</VL>
<NO>2</NO>
<PG>171-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guyatt-1987" NAME="Guyatt 1987" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Townsend M, Pugsley SO, Keller JL, Short HD, Taylor W, et al</AU>
<TI>Bronchilators in chronic air-flow limitation</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1987</YR>
<VL>135</VL>
<PG>1069-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guyatt-1988" NAME="Guyatt 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Townsend M, Nogradi S, Pugsley SO, Keller JL, Newhouse MT</AU>
<TI>Acute responses to bronchodilator - an imperfect guide for bronchodilator therapy in chronic airflow limitation</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1988</YR>
<VL>148</VL>
<PG>1949-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guyatt-1989" NAME="Guyatt 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Townsend M, Keller JL, Singer J</AU>
<TI>Should study subjects see their previous responses: data from a randomized control trial</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1989</YR>
<VL>42</VL>
<NO>9</NO>
<PG>913-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hansen-1990" NAME="Hansen 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hansen NC, May O</AU>
<TI>Domiciliary nebulised terbutaline in severe chronic airways obstruction</TI>
<SO>European Respiratory Journal</SO>
<YR>1990</YR>
<VL>3</VL>
<PG>463-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jaeschke-1991" NAME="Jaeschke 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jaeschke R, Guyatt GH, Singer J, Keller J, Newhouse MT</AU>
<TI>Mechanism of bronchodilator effect in chronic airflow limitation</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1991</YR>
<VL>144</VL>
<NO>1</NO>
<PG>35-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klock-1975" NAME="Klock 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klock LE, Miller TD, Morris AH, Watanabe S, Dickman M</AU>
<TI>A comparative study of atropine sulphate and isoproterenol hydrochloride in chronic bronchitis</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1975</YR>
<VL>112</VL>
<PG>371-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Light-1975" NAME="Light 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Light RW, Summer WR, Luchsinger PC</AU>
<TI>Response of patients with chronic obstructive lung disease to the regular administration of nebulized isoproterenol</TI>
<SO>Chest</SO>
<YR>1975</YR>
<VL>67</VL>
<NO>6</NO>
<PG>634-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shah-1983" NAME="Shah 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shah SS, Johnsonton D, Woodcock AA, Johnson M, Geddes DM</AU>
<TI>Breathlessness and exercise tolerance in chronic airflow obstruction: 2-hourly versus 4-hourly salbutamol by inhalation</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>1983</YR>
<VL>8</VL>
<NO>5</NO>
<PG>345-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Silins-1985" NAME="Silins 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Silins RA, Marlin GE</AU>
<TI>Evaluation of domiciliary treatment with terbutaline by wet nebulisation in patients with chronic bronchitis and emphysema</TI>
<SO>Australian and New Zealand Journal of Medicine</SO>
<YR>1985</YR>
<VL>15</VL>
<PG>230-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tandon-1990" NAME="Tandon 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tandon MK, Kailis SG</AU>
<TI>Bronchodilator treatment for partially reversible chronic obstructive airways disease</TI>
<SO>Thorax</SO>
<YR>1991</YR>
<VL>46</VL>
<PG>248-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taylor-1985" NAME="Taylor 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taylor DR, Buick B, Kinney C, Lowry RC, McDevitt DG</AU>
<TI>The efficacy of orally administered theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible air-flow obstruction</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1985</YR>
<VL>131</VL>
<PG>747-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilson-1980" NAME="Wilson 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilson RS, Connellan SJ</AU>
<TI>Domicillary nebulised salbutamol solution in severe chronic airway obstruction</TI>
<SO>Thorax</SO>
<YR>1980</YR>
<VL>35</VL>
<PG>873-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Aalto-1992" NAME="Aalto 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aalto E, Havu M, Kotaniemi J, Nieminen P, Svahn T, Svensson M, et al</AU>
<TI>Comparison of terbutaline turbuhaler and albuterol chlorofluorocarbon (CFC) inhaler in middle-aged and elderly patients with obstructive lung disease</TI>
<SO>Annals of Allergy</SO>
<YR>1992</YR>
<VL>69</VL>
<PG>33-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Allen-1988" NAME="Allen 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Allen MB, Pugh J, Wilson RS</AU>
<TI>Nebuhaler or nebulizer for high dose bronchodilator therapy in chronic bronchitis: a comparison</TI>
<SO>British Journal of Diseases of the Chest</SO>
<YR>1988</YR>
<VL>82</VL>
<PG>368-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aquilina-1986" NAME="Aquilina 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aquilina R, Bergero F, Noceti P, Mirabelli S, Luciani G</AU>
<TI>Protective effect of Dovent versus salbutamol in long-term treatment</TI>
<SO>Respiration</SO>
<YR>1986</YR>
<VL>50</VL>
<NO>Suppl 2</NO>
<PG>240-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Backman-1985" NAME="Backman 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Backman R, Hellstrom PE</AU>
<TI>Fenoterol and ipratropium bromide in respiratory treatment of patients with chronic bronchitis</TI>
<SO>Current Therapeutic Research</SO>
<YR>1985</YR>
<VL>38</VL>
<NO>1</NO>
<PG>135-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blosser-1995" NAME="Blosser 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blosser SA, Maxwell SL, Reeves-Hoche MK, Localio AR, Zwillich CW</AU>
<TI>Is an anticholinergic agent superior to a beta-2 agonist in improving dyspnea and exercise limitation in COPD?</TI>
<SO>Chest</SO>
<YR>1995</YR>
<VL>108</VL>
<PG>730-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bossert-1989" NAME="Bossert 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bossert von J, Trager E</AU>
<TI>Additive effects of combination treatment of salbutamol and slow-release theophylline as compared with salbutamol alone</TI>
<TO>Theophylline plus Salbutamol bei chronischer bronchialobstruction</TO>
<SO>Fortschritte der Medizin</SO>
<YR>1989</YR>
<VL>107</VL>
<NO>11</NO>
<PG>255-8/67-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Christensen-1991_x0028_a_x0029_" NAME="Christensen 1991(a)" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christensen EF, Dahl R</AU>
<TI>Treatment of chronic bronchitis with terbutaline inhaled from a cone spacer with or without positive expiratory pressure</TI>
<SO>Lung</SO>
<YR>1991</YR>
<VL>169</VL>
<PG>325-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Christensen-1991_x0028_b_x0029_" NAME="Christensen 1991(b)" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christensen EF, Norregaard O, Dahl R</AU>
<TI>Nebulized terbutaline and positive expiratory pressure in chronic obstructive pulmonary disease</TI>
<SO>Pneumologie</SO>
<YR>1991</YR>
<VL>45</VL>
<PG>105-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Combivent-1994" NAME="Combivent 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Combivent Inhalation Aerosol Study Group</AU>
<TI>In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone</TI>
<SO>Chest</SO>
<YR>1994</YR>
<VL>105</VL>
<PG>1411-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Combivent-1997" NAME="Combivent 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Combivent Inhalation Solution Study Group</AU>
<TI>Routine nebulized ipratropium and albuterol together are better than either alone in COPD</TI>
<SO>Chest</SO>
<YR>1997</YR>
<VL>112</VL>
<PG>1514-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Connellan-1979" NAME="Connellan 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Connellan SJ, Wilson RSE</AU>
<TI>The use of domiciliary nebulized salbutamol in the treatment of severe emphysema</TI>
<SO>British Journal of Clinical Practice</SO>
<YR>1979</YR>
<PG>135-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Connolly-1987" NAME="Connolly 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Connolly CK, Chan NS</AU>
<TI>Salbutamol and ipratropium in partially reversible airway obstruction</TI>
<SO>Chest</SO>
<YR>1987</YR>
<VL>81</VL>
<PG>55-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cook-2001" NAME="Cook 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cook D, Guyatt G, Wong E, Goldstein R, Bedard M, Austin P, et al</AU>
<TI>Regular versus as-needed short-acting inhaled beta-agonist therapy for chronic obstructive pulmonary disease</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>2001</YR>
<VL>163</VL>
<NO>1</NO>
<PG>85-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Emirgil-1969" NAME="Emirgil 1969" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Emirgil C, Sobol BJ, Norman J, Moskowitz E, Goyal P, Wadhwani B, et al</AU>
<TI>A study of the long-term effect of therapy in chronic obstructive pulmonary disease</TI>
<SO>American Journal of Medicine</SO>
<YR>1969</YR>
<VL>47</VL>
<PG>367-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grassi-1986" NAME="Grassi 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grassi V, Bruni B, Peccini F, Tantucci C, Todisco T</AU>
<TI>Acute on chronic comparative effects of a combination of fenoterol-ipratropium bromide and terbutaline in patients with chronic obstructive lung diseases</TI>
<SO>Respiration</SO>
<YR>1986</YR>
<VL>50</VL>
<NO>Suppl 2</NO>
<PG>226-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hansen-1994" NAME="Hansen 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hansen NCG, Evald T, Ibsen TB</AU>
<TI>Terbutaline inhalations by the turbuhaler as replacement for domiciliary nebulizer therapy in severe chronic obstructive pulmonary disease</TI>
<SO>Respiratory Medicine</SO>
<YR>1994</YR>
<VL>88</VL>
<PG>267-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ibsen-1990" NAME="Ibsen 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Ibsen TB. Svendsen UG. [The significance of incorrect spray technic on the consumption of terbutaline in patients with chronic obstructive lung disease].&lt;br&gt;[Danish] [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] Ugeskrift for Laeger. 152(19):1375-8, 1990 May 7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ibsen TB, Svedsen UG and Turbuhaler Multicentergruppen</AU>
<TI>The significance of incorrect spray technique on the consumption of terbutaline in patients with chronic obstructive lung disease (article in Danish)</TI>
<TO>Betydningen af fejlagtig sprayteknik pa terbutalinforbruget hos patienter med kronisk obstructiv lungesyngdom</TO>
<SO>Ugeskrift for Laeger</SO>
<YR>1990</YR>
<VL>152</VL>
<NO>19</NO>
<PG>1375-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jaeschke-1994" NAME="Jaeschke 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jaeschke R, Guyatt GH, Willan A, Cook D, Harper S, Morris J, et al</AU>
<TI>Effect of increasing doses of beta agonists on spirometric parameters, exercise capacity, and quality of life in patients with chronic airway limitation</TI>
<SO>Thorax</SO>
<YR>1994</YR>
<VL>49</VL>
<PG>479-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jenkins-1987" NAME="Jenkins 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jenkins SC, Heaton RW, Fulton TJ, Moxam J</AU>
<TI>Comparison of domiciliary nebulized salbutamol and salbutamol from a metered-dose inhaler in stable chronic airflow limitation</TI>
<SO>Chest</SO>
<YR>1987</YR>
<VL>91</VL>
<NO>6</NO>
<PG>804-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klein-1964" NAME="Klein 1964" YEAR="1964">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klein RC, Salvaggio JE, Kundur VG</AU>
<TI>The response of patients with "idiopatic" obstructive pulmonary disease and "allergic" obstructive bronchitis to prednisone</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1964</YR>
<VL>71</VL>
<NO>4</NO>
<PG>711-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lighbody-1978" NAME="Lighbody 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lightbody IM, Ingram CG, Legge JS, Johnston RN</AU>
<TI>Ipratropium bromide, salbutamol and prednisolone in bronchial asthma and chronic bronchitis</TI>
<SO>British Journal of Diseases of the Chest</SO>
<YR>1978</YR>
<VL>72</VL>
<PG>181-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lipworth-1990" NAME="Lipworth 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lipworth BJ, Clark RA, Dhillon DP, Mcdevitt DG</AU>
<TI>Comparison of the effects of prolonged treatment with low and high doses of inhaled terbutaline on beta-adrenoceptor responsiveness in patients with chronic obstructive pulmonary disease</TI>
<SO>American Review of Respiratory Diseases</SO>
<YR>1990</YR>
<VL>142</VL>
<PG>338-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McGivern-1984" NAME="McGivern 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McGivern DV, Ward M, Revill S, Sechiari A, Macfarlane J, Davies D</AU>
<TI>Home nebulizers in severe chronic asthma</TI>
<SO>British Journal of Diseases of the Chest</SO>
<YR>1984</YR>
<VL>78</VL>
<PG>376-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McIntosh-1983" NAME="McIntosh 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McIntosh D</AU>
<TI>A trial of fenoterol for nocturnal bronchospasm</TI>
<SO>The Practitioner</SO>
<YR>1983</YR>
<VL>227</VL>
<PG>1757-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mestitz-1989" NAME="Mestitz 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mestitz H, Copland JM, McDonald CF</AU>
<TI>Comparison of outpatient nebulized vs metered dose inhaler terbutaline in chronic airflow obstruction</TI>
<SO>Chest</SO>
<YR>1989</YR>
<VL>96</VL>
<NO>6</NO>
<PG>1237-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morrison-1992" NAME="Morrison 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morrison JGJ, Jones PC, Muers MF</AU>
<TI>Assessing physiological benefit from domiciliary nebulized bronchodilators in severe airflow limitation</TI>
<SO>European Respiratory Journal</SO>
<YR>1992</YR>
<VL>5</VL>
<PG>424-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nishimura-1995" NAME="Nishimura 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nishimura K, Koyama H, Ikeda A, Sugiura N, Kawakatsu K, Izumi T</AU>
<TI>The additive effect of theophylline on a high-dose combination of inhaled salbutamol and ipratropium bromide in stable COPD</TI>
<SO>Chest</SO>
<YR>1995</YR>
<VL>107</VL>
<PG>718-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Driscoll-1990" NAME="O'Driscoll 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Driscoll BR, Kay EA, Taylor RJ, Bernstein A</AU>
<TI>Home nebulizers: can optimal therapy be predicted by laboratory studies?</TI>
<SO>Respiratory Medicine</SO>
<YR>1990</YR>
<VL>84</VL>
<PG>471-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Driscoll-1992" NAME="O'Driscoll 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Driscoll BR, Kay EA, Taylor RJ, Weatherby H, Chetty MCP,Bernstein A</AU>
<TI>A long-term prospective assessment of home nebulizer treatment</TI>
<SO>Respiratory Medicine</SO>
<YR>1992</YR>
<VL>317</VL>
<PG>317-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Driscoll-1996" NAME="O'Driscoll 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Driscoll BR, Bernstein A</AU>
<TI>A long-term study of symptoms, spirometry and survival amongst home nebulizer users</TI>
<SO>Respiratory Medicine</SO>
<YR>1996</YR>
<VL>90</VL>
<PG>561-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pedersen-1979" NAME="Pedersen 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petersen BN, Weeke E</AU>
<TI>Ipratropium or terbutaline</TI>
<TO>Ipratropium or terbutaline. En sammenlignende undersegreise hos 19 patienter med kronisk obstruktive lungelideiser</TO>
<SO>Ugeskrift for Laeger</SO>
<YR>1979</YR>
<VL>141</VL>
<NO>36</NO>
<PG>2439-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perri-1985" NAME="Perri 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perri G, Giovannini M, Spada E</AU>
<TI>Salbutamol plus bechlomethsone dipropionate (Ventolin Flogo) vs. fenoterol (Dosberotec) in chronic obstructive lung disease therapeutic strategy: a 4 week clinical trial</TI>
<SO>International Journal of Clinical Pharmacology Therapeutics &amp; Toxicology</SO>
<YR>1985</YR>
<VL>23</VL>
<NO>5</NO>
<PG>274-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petro-1981" NAME="Petro 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petro W, Nakhosten JA, Konietzko N</AU>
<TI>Bronchodilator effect of a combination of a beta-adrenergic agonist and a cholinergic antagonist</TI>
<TO>Broncholyse unter kombinierter Anwendung von beta-adrenergen Agonisten und cholinergen Antagonisten</TO>
<SO>Praxis und Klinik der Pneumologie</SO>
<YR>1981</YR>
<VL>35</VL>
<PG>779-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petty-1984" NAME="Petty 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petty TL, Scoggin CH, Rollins DR, Repsher LH</AU>
<TI>Bitolterol compared to isoproterenol in advanced chronic obstructive pulmonary disease</TI>
<SO>Chest</SO>
<YR>1984</YR>
<VL>86</VL>
<NO>3</NO>
<PG>404-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stalenheim-1994" NAME="Stalenheim 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stalenheim G, Wegener T, Grettve L, Lundback B, Melander B, Osterman K, et al</AU>
<TI>Efficacy and tolerance of a 12-week treatment with inhaled formoterol in patients with reversible obstructive lung disease</TI>
<SO>Respiration</SO>
<YR>1994</YR>
<VL>61</VL>
<PG>305-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stiksa-1984" NAME="Stiksa 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stiksa G, Nemcek K, Melin S</AU>
<TI>Effects of inhaled N-acetylcysteine in combination with terbutaline</TI>
<SO>European Journal of Respiratory Diseases</SO>
<YR>1984</YR>
<VL>65</VL>
<PG>278-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tanser-1982" NAME="Tanser 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tanser AR</AU>
<TI>Maintenance of bronchodilation in chronic reversible airways obstruction. Comparison between choline theophyllinate and salbutamol</TI>
<SO>The Practitioner</SO>
<YR>1982</YR>
<VL>226</VL>
<PG>569-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Teale-1991" NAME="Teale 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Teale C, Morrison JFJ, Jones PC, Muers MF</AU>
<TI>Reversibility tests in chronic obstructive airways disease: their predictive value with reference to benefit from domiciliary nebulizer therapy</TI>
<SO>Respiratory Medicine</SO>
<YR>1991</YR>
<VL>85</VL>
<PG>251-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Schayck-1991" NAME="van Schayck 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Schayck CP, Dompeling E, van Herwaarden CLA, Folgering H, Verbeek ALM, van der Hoogen HJM, et al</AU>
<TI>Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomized controlled study</TI>
<SO>British Medical Journal</SO>
<YR>1991</YR>
<VL>303</VL>
<PG>1426-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Schayck-1992" NAME="van Schayck 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Schayeck CP, Rutten-van Molken MPMH, van Doorslaer EKA, Folgering H, van Weel C</AU>
<TI>Two-year bronchodilator treatment in patients with mild airflow obstruction. Contradictory effects on lung function and quality of life</TI>
<SO>Chest</SO>
<YR>1992</YR>
<VL>102</VL>
<PG>1384-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Schayck-1994" NAME="van Schayck 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Schayck CP, Folgering H, den Otter JJ, Tirimanna P, van Weel C</AU>
<TO>Maskeert continu gebruik van bronchusverwijders de progressie van cara?</TO>
<SO>Tijdschrift Voor Geneeskunde</SO>
<YR>1994</YR>
<VL>50</VL>
<PG>787-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Schayck-1995" NAME="van Schayck 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Schayck CP, Dompeling E, van Herwaarden CL, Folgering H, van der Broek PJ, van Weel C</AU>
<TI>Continuous and on demand use of bronchodilators in patients with non-steroid dependent asthma and chronic bronchitis: four-year follow-up randomized control study</TI>
<SO>British Journal of Clinical Practice</SO>
<YR>1995</YR>
<VL>45</VL>
<PG>239-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ydreborg-1997" NAME="Ydreborg 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ydreborg S O, Svedmyr N, Thiringer G</AU>
<TI>Comparison of rimiterol and terbutaline, given by aerosol, in a long-term study</TI>
<SO>Scandinivian Journal of Respiratory Diseases</SO>
<YR>1997</YR>
<VL>58</VL>
<PG>117-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-08-22 16:16:28 +0100" MODIFIED_BY="Toby J Lasserson">
<ADDITIONAL_REFERENCES MODIFIED="2008-08-22 16:16:28 +0100" MODIFIED_BY="Toby J Lasserson">
<REFERENCE ID="REF-Appleton-2000" MODIFIED="2008-08-22 16:16:28 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Appleton 2000" TYPE="COCHRANE_REVIEW">
<AU>Appleton S, Smith B, Veale A, Bara A</AU>
<TI>Long-acting beta2-agonists for chronic obstructive pulmonary disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>2</NO>
<PG>CD001104</PG>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10796594"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bellamy-1981" MODIFIED="2008-08-22 16:16:28 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Bellamy 1981" TYPE="JOURNAL_ARTICLE">
<AU>Bellamy D, Hutchinson DCF</AU>
<TI>The effects of salbutamol aerosol on lung function in patients with pulmonary emphysema</TI>
<SO>British Journal of Diseases of the Chest</SO>
<YR>1981</YR>
<VL>75</VL>
<PG>190-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cleophas-1993" MODIFIED="2008-08-22 16:16:28 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Cleophas 1993" TYPE="JOURNAL_ARTICLE">
<AU>Cleophas TJ</AU>
<TI>Carry-over biases in clinical pharmacology</TI>
<SO>European Journal of Clinical Chemistry &amp; Clinical Biochemistry</SO>
<YR>1993</YR>
<VL>31</VL>
<NO>12</NO>
<PG>803-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cleophas-1996a" MODIFIED="2008-08-22 16:16:28 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Cleophas 1996a" TYPE="JOURNAL_ARTICLE">
<AU>Cleophas TJ</AU>
<TI>Clinical trials: relevance of correlation between treatment responses</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1996</YR>
<VL>50</VL>
<NO>1-2</NO>
<PG>1-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cleophas-1996b" MODIFIED="2008-08-22 16:16:28 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Cleophas 1996b" TYPE="JOURNAL_ARTICLE">
<AU>Cleophas TJ</AU>
<TI>Crossover trials are only useful when there is a positive correlation between the response to different treatment modalities</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1996</YR>
<VL>41</VL>
<NO>3</NO>
<PG>235-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Connellan-1982" MODIFIED="2008-08-22 16:16:28 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Connellan 1982" TYPE="JOURNAL_ARTICLE">
<AU>Connellan SJ, Gough SE</AU>
<TI>The effects of nebulized salbutamol on lung function and exercise tolerance in patients with severe airway obstruction</TI>
<SO>British Journal of Diseases of the Chest</SO>
<YR>1982</YR>
<VL>76</VL>
<PG>135-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Formgren-1994" MODIFIED="2008-08-22 16:16:28 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Formgren 1994" TYPE="JOURNAL_ARTICLE">
<AU>Formgren H, Sjokvist A, Stahl E, Wiren JE</AU>
<TI>Terbutaline in COPD comparison between turbuhaler and chloroflurocarbon (CFC) inhaler</TI>
<SO>Lung</SO>
<YR>1994</YR>
<VL>172</VL>
<PG>271-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-1986" MODIFIED="2008-08-22 16:16:28 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Guyatt 1986" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt G, Sackett D, Taylor DW, Chong J, Roberts R, Pugsley S</AU>
<TI>Determining optimal therapy- Randomized trials in individual patients</TI>
<SO>New England Journal of Medicine</SO>
<YR>1986</YR>
<VL>314</VL>
<PG>889-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-1987a" NAME="Guyatt 1987a" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW</AU>
<TI>A measure of quality of life for clinical trials in chronic lung disease</TI>
<SO>Thorax</SO>
<YR>1987</YR>
<VL>42</VL>
<PG>773-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ikeda-1999" MODIFIED="2008-08-22 16:16:28 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Ikeda 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ikeda A, Nishimura K, Koyama H, Tsukino M, Hajiro T, Mishima M, et al</AU>
<TI>Comparison of the bronchodilator effects of salbutamol delivered via a metered-dose inhaler with spacer, a dry-powder inhaler, and a jet nebulizer in patients with chronic obstructive pulmonary disease</TI>
<SO>Respiration</SO>
<YR>1999</YR>
<VL>66</VL>
<PG>119-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Iversen-1999" MODIFIED="2008-08-22 16:16:28 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Iversen 1999" TYPE="JOURNAL_ARTICLE">
<AU>Iversen ET, Sorensen T, Heckscher T, Jensen JI</AU>
<TI>Effect of terbutaline on exercise capacity and pulmonary function in patients with chronic obstructive pulmonary disease</TI>
<SO>Lung</SO>
<YR>1999</YR>
<VL>177</VL>
<PG>263-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Murariu--1998" MODIFIED="2008-08-22 16:16:28 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Murariu  1998" TYPE="JOURNAL_ARTICLE">
<AU>Murariu C, Ghezzo H, Milic-Emili J, Gautier H</AU>
<TI>Exercise limitation in obstructive lung disease</TI>
<SO>Chest</SO>
<YR>1998</YR>
<VL>114</VL>
<PG>965-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mutterlein-1990" MODIFIED="2008-08-22 16:16:28 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Mutterlein 1990" TYPE="JOURNAL_ARTICLE">
<AU>Mutterlein VR, Schmidt G, Fleischer W, Freund E</AU>
<TI>A new inhalation system for bronchodilation. A study of the acceptance of the Ingelheim M inhalator by chronic obstructive pulmonary disease patients</TI>
<TO>Ein neues inhalationssystem zur bronchodilation</TO>
<SO>Fortscritte der Therapie (Pneumologie)</SO>
<YR>1990</YR>
<VL>108</VL>
<NO>11</NO>
<PG>225-8/61-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Noseda-1995" MODIFIED="2008-08-22 16:16:28 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Noseda 1995" TYPE="JOURNAL_ARTICLE">
<AU>Noseda A, Schmerber J, Prigogine T, deMaertelaer V, Yernault J-C</AU>
<TI>Perception of dyspnea during acute changes in lung function in patients with either asthma or COPD</TI>
<SO>Respiratory Medicine</SO>
<YR>1995</YR>
<VL>89</VL>
<PG>477-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Poole-1998" MODIFIED="2008-08-22 16:16:28 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Poole 1998" TYPE="JOURNAL_ARTICLE">
<AU>Poole PJ, Brodie SM, Stewart JM, Black PN</AU>
<TI>The effects of nebulised isotonic saline and terbutaline on breathlessness in severe chronic obstructive pulmonary disease</TI>
<SO>Australia New Zealand Journal of Medicine</SO>
<YR>1998</YR>
<VL>28</VL>
<NO>3</NO>
<PG>322-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Redelmeier-1997" MODIFIED="2008-08-22 16:16:28 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Redelmeier 1997" TYPE="JOURNAL_ARTICLE">
<AU>Redelmeier DA, Bayoumi AM, Goldstein RS, Guyatt GH</AU>
<TI>Interpreting small differences in functional status: the Six Minute Walk test in chronic lung disease patients</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1997</YR>
<VL>155</VL>
<NO>4</NO>
<PG>1278-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tantucci-1999" MODIFIED="2008-08-22 16:16:28 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Tantucci 1999" TYPE="JOURNAL_ARTICLE">
<AU>Tantucci C, Grassi V</AU>
<TI>Flow limitation: an overview</TI>
<SO>Monaldi Archives of Chest Diseases</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>4</NO>
<PG>353-7</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-08-22 16:18:27 +0100" MODIFIED_BY="Toby J Lasserson">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-08-22 16:18:27 +0100" MODIFIED_BY="Toby J Lasserson" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-08-22 16:18:27 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Dullinger-1986">
<CHAR_METHODS MODIFIED="2008-08-22 16:18:27 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Randomised, double-blind placebo controlled, crossover study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>10 male patients with slowly progressive exertion , FEV1&lt;1.5L and no history of asthma.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Week-long treatment with metaproterenol, 1.3 mg from a metered dose canister or placebo six times a day and oral theophylline or placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1, FVC, 12 min walking test, oxygen cost diagram, progressive cycle ergometry.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Guyatt-1987">
<CHAR_METHODS>
<P>Randomised, double-blind placebo controlled, cross-over study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>27 male patients with FEV1&lt;70% of predicted and FEV1/VC ratio&lt;0.7. Less than 25% increase in FEV1 after salbutamol.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 week-long treatment with inhaled salbutamol 200 ug qid and/or oral theophylline.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PEFR, spirometry, 6 min walking test, clinical symptoms of dyspnea, fatigue and emotional function.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Guyatt-1988">
<CHAR_METHODS>
<P>Same as Guyatt 1987</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>32 male patients (same as in Guyatt 1987 plus 5 additional patients with more than 25% increase in FEV1 after salbutamol)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Same as Guyatt 1987.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Spirometry, walk test, CRQ physical function.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Guyatt-1989">
<CHAR_METHODS>
<P>Same as Guyatt 1987 and 1988</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Same as Guyatt 1988.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Same as Guyatt 1987 and 1988.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Spirometry, walk test, dyspnea, fatigue, emotional function, mastery.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hansen-1990">
<CHAR_METHODS>
<P>Randomised, double-blind placebo controlled, cross-over study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>48 patients (24 men) with a history of chronic bronchitis, FEV1&lt;1 liter, never treated with a nebuliser or oxygen at home. Patients with a decrease in FEV1 after terbutaline were excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>5 mg terbutaline or placebo from a nebuliser twice daily for 2+2 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Spirometry, PEFR, 6 min walk test, dyspnea (visual analogue scale), preference.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Jaeschke-1991">
<CHAR_METHODS>
<P>Randomised, double-blind placebo controlled, cross-over study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>24 patients (same who completed Guyatt 1988).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Same as Guyatt 1987.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Spirometry, maximal inspiratory pressure, dyspnea score.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Klock-1975">
<CHAR_METHODS>
<P>Randomised, double-blind placebo controlled, cross-over study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>15 patients (12 men) with ATS 1962 criteria for chronic bronchitis and FEV1&lt;65% of predicted.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>3-week period of 20 sprays (1 mg) of 1:100 atropine sulphate, 1:100 isoproterenol HCl, or placebo qid from a DeVilbiss hand nebuliser.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Spirometry, Raw, FRC, symptoms (more, equal, less).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Light-1975">
<CHAR_METHODS>
<P>Randomised, double-blind placebo controlled, cross-over study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>16 patients with FEV1 &lt;2 L and &lt;60% of FVC or &lt;50% of FVC.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>8-week period of isoproterenol 250 mg or placebo from nebuliser qid.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Spirometry, Raw, PO2, PCO2, preference.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Shah-1983">
<CHAR_METHODS>
<P>Randomised, double-blind placebo controlled, cross-over study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>12 patients with COPD (mean FEV1 0.6 L) and one &gt;15%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1 week treatment with 200 ug salbutamol 4-hourly, 2-hourly or placebo from metered canister.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Spirometry, 6 min walk, breathlessness, PEFR.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Silins-1985">
<CHAR_METHODS>
<P>Randomised, double-blind placebo controlled, cross-over study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>8 male patients with severe airflow limitation due to COPD, previously on chronic treatment with inhaled beta-2 agonist.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Four 1-week period, 2 with terbutaline 5 mg qid and 2 with placebo from nebuliser.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Spirometry, RV, TLC, FRC (helium dilution), PEFR, symptoms, (4 points scale).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tandon-1990">
<CHAR_METHODS>
<P>Randomised, double-blind placebo controlled, cross-over study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>37 men with a history of chronic bronchitis, FEV1 &lt;65% of predicted in the past 2 years. More than 15% increase in FEV1 after salbutamol, need for regular treatment with beta-agonists.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>6 week-long treatment with 4 puffs terbutaline (1 mg) qid and oral theophylline bid.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PEFR, spirometry, treatment failures.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Taylor-1985">
<CHAR_METHODS>
<P>Randomised, double-blind placebo controlled, cross-over study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>25 patients (21 men) with chronic bronchitis (MRC 1965) and &gt;10% improvement in FEV1 after salbutamol.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Four 3-week periods with 200 ug salbutamol or placebo qid from metered canisters and/or oral theophylline bid.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Spirometry, RV, TLC, (helium dilution), preference symptoms (5 point scale of change from baseline).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wilson-1980">
<CHAR_METHODS>
<P>Randomised, double-blind placebo controlled, cross-over study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>10 patients (9 men) with severe chronic airway obstruction and marked dyspnea, not improved after high-dose oral steroids.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 week-long periods with 5 mg salbutamol or placebo qid from a nebuliser.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PEFR, Symptoms (4 point scale).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Aalto-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group. Asthma not excluded</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Allen-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Aquilina-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Placebo arm not randomised. Asthma not excluded. Responsive patients selected (&gt;15% FEV1)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Backman-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group. Not in stable patients (acute exacerbations)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Blosser-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group. Only responsive patients (&gt;15% FEV1)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bossert-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Christensen-1991_x0028_a_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>No Placebo group. Open trial. Patients with severe obstruction (FEV1 &lt;1 L) excluded.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Christensen-1991_x0028_b_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Combivent-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Combivent-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Connellan-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Connolly-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Asthma not excluded. No placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cook-2001">
<CHAR_REASON_FOR_EXCLUSION/>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Emirgil-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Grassi-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group. Responsive patients selected (&gt;+15% FEV1)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hansen-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ibsen-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jaeschke-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jenkins-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Klein-1964">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group. Single blinded study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lighbody-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lipworth-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McGivern-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo arm. Asthma not excluded</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McIntosh-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group. No information on treatment doses.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mestitz-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Morrison-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>No beta agonist used alone, only in combination with ipratropium.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nishimura-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>No beta agonist used alone, only in combination with ipratropium. No placebo group..</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-O_x0027_Driscoll-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-O_x0027_Driscoll-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-O_x0027_Driscoll-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Asthma not excluded. No placebo group and not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pedersen-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Only 3 days. No placebo. Asthma not excluded</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Perri-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo arm. Responsive patients selected (&gt;+15% FEV1)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Petro-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo. No treatment with beta-agonist alone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Petty-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo arm. Responsive patients selected (&gt;+15% FEV1)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stalenheim-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo arm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stiksa-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo arm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tanser-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo arm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Teale-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>No beta agonist alone, only in combination with ipratropium</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-van-Schayck-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo arm. Asthma not excluded.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-van-Schayck-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo arm. Asthma not excluded.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-van-Schayck-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo arm. Asthma not excluded.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-van-Schayck-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo arm. Asthma not excluded.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ydreborg-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo arm. Combination of oral and inhaled beta-2 agonist used.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-08-22 16:19:51 +0100" MODIFIED_BY="Toby J Lasserson">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-08-22 16:19:51 +0100" MODIFIED_BY="Toby J Lasserson" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 16:18:44 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Dullinger-1986">
<DESCRIPTION>
<P>Investigators aware as to order of treatment group assignment (Cochrane Grade A)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 16:19:00 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Guyatt-1987">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 16:19:08 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Guyatt-1988">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 16:19:11 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Guyatt-1989">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 16:19:14 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Hansen-1990">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 16:19:16 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Jaeschke-1991">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 16:19:19 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Klock-1975">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 16:19:21 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Light-1975">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 16:19:24 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Shah-1983">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 16:19:28 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Silins-1985">
<DESCRIPTION>
<P>Information not available (Cochrane Grade B)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 16:19:42 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Tandon-1990">
<DESCRIPTION>
<P>Investigators aware as to order of treatment group assignment (Cochrane Grade A)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 16:19:47 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Taylor-1985">
<DESCRIPTION>
<P>Investigators aware as to order of treatment group assignment (Cochrane Grade A)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 16:19:51 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Wilson-1980">
<DESCRIPTION>
<P>Investigators aware as to order of treatment group assignment (Cochrane Grade A)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-08-22 16:16:28 +0100" MODIFIED_BY="Toby J Lasserson">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-08-22 16:16:28 +0100" MODIFIED_BY="Toby J Lasserson" NO="1">
<TITLE>Characteristics of patients in included studies at baseline</TITLE>
<TABLE COLS="10" ROWS="17">
<TR>
<TH>
<P>Paper</P>
</TH>
<TH>
<P>Patients (females)</P>
</TH>
<TH>
<P>Mean age (range)</P>
</TH>
<TH>
<P>Ex smokers</P>
</TH>
<TH>
<P>Respiratory function</P>
</TH>
<TH>
<P>Reversibility</P>
</TH>
<TH>
<P>Drug</P>
</TH>
<TH>
<P>Duration/washout</P>
</TH>
<TH>
<P>Steroids</P>
</TH>
<TH>
<P>Other medications</P>
</TH>
</TR>
<TR>
<TD>
<P>Light 1975<BR/>
</P>
</TD>
<TD>
<P>16 (1)</P>
</TD>
<TD>
<P>? (48-68)</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>FEV1/VC &lt;50%</P>
</TD>
<TD>
<P>Wide range</P>
</TD>
<TD>
<P>Isoprot 0.25 mgx4 mistometer</P>
</TD>
<TD>
<P>8 weeks /2 weeks</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD>
<P>None allowed</P>
</TD>
</TR>
<TR>
<TD>
<P>Klock 1975</P>
</TD>
<TD>
<P>15 (3)</P>
</TD>
<TD>
<P>56 (32-72)</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>FEV1/VC &lt;65%</P>
</TD>
<TD>
<P>Wide range</P>
</TD>
<TD>
<P>Isoprot 1mgx4 hand-bulb</P>
</TD>
<TD>
<P>3 weeks /10 hours</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD>
<P>Discontinued</P>
</TD>
</TR>
<TR>
<TD>
<P>Dullinger 1986</P>
</TD>
<TD>
<P>10 (?)</P>
</TD>
<TD>
<P>61 (53-72)</P>
</TD>
<TD>
<P>all</P>
</TD>
<TD>
<P>FEV1/VC &lt;60%</P>
</TD>
<TD>
<P>&lt;25%</P>
</TD>
<TD>
<P>Isoprot 0.65 mgX4/5 MDI</P>
</TD>
<TD>
<P>1 week /?</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Wilson 1980</P>
</TD>
<TD>
<P>5 (1)</P>
</TD>
<TD>
<P>? (47-81)</P>
</TD>
<TD>
<P>all (1 current)</P>
</TD>
<TD>
<P>FEV1 &lt;1L</P>
</TD>
<TD>
<P>"small"</P>
</TD>
<TD>
<P>Salbut 5mgx4 nebuliser</P>
</TD>
<TD>
<P>2 weeks /?</P>
</TD>
<TD>
<P>low (3 on 5 mg)</P>
</TD>
<TD>
<P>Rescue beta agonist</P>
</TD>
</TR>
<TR>
<TD>
<P>Taylor 1985</P>
</TD>
<TD>
<P>28 (4)</P>
</TD>
<TD>
<P>63 (45-73)</P>
</TD>
<TD>
<P>23 (4 current)</P>
</TD>
<TD>
<P>FEV1 15-78%</P>
</TD>
<TD>
<P>&gt;10%</P>
</TD>
<TD>
<P>Sabut 0.2 mgx4 MDI</P>
</TD>
<TD>
<P>3 weeks /?</P>
</TD>
<TD>
<P>inhaled (some)</P>
</TD>
<TD>
<P>Discontinued</P>
</TD>
</TR>
<TR>
<TD>
<P>Shah 1983</P>
</TD>
<TD>
<P>12 (?)</P>
</TD>
<TD>
<P>62 (52-74)</P>
</TD>
<TD>
<P>12 (2 current)</P>
</TD>
<TD>
<P>FEV1 0.2-1.2 L</P>
</TD>
<TD>
<P>&lt;15%</P>
</TD>
<TD>
<P>Salbut 0.2 mg x5/8 MDI</P>
</TD>
<TD>
<P>1 week /?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Beta agonist stopped</P>
</TD>
</TR>
<TR>
<TD>
<P>Silins 1985</P>
</TD>
<TD>
<P>8 (0)</P>
</TD>
<TD>
<P>? (64-74)</P>
</TD>
<TD>
<P>all</P>
</TD>
<TD>
<P>FEV1 0.4-1.6 L</P>
</TD>
<TD>
<P>"low"</P>
</TD>
<TD>
<P>Terbut 1 mgx4 MDI</P>
</TD>
<TD>
<P>2 weeks /?</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>Usual meds continued</P>
</TD>
</TR>
<TR>
<TD>
<P>Tandon 1991</P>
</TD>
<TD>
<P>37 (0)</P>
</TD>
<TD>
<P>70 (55-85)</P>
</TD>
<TD>
<P>all (10 current)</P>
</TD>
<TD>
<P>FEV1 &lt;65%</P>
</TD>
<TD>
<P>&gt;15%</P>
</TD>
<TD>
<P>Terbut 1 mgx4 MDI</P>
</TD>
<TD>
<P>6 weeks /?</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>Usual meds continued</P>
</TD>
</TR>
<TR>
<TD>
<P>Hansen 1990</P>
</TD>
<TD>
<P>48 (24)</P>
</TD>
<TD>
<P>66 (45-83)</P>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P>FEV1 &lt;1L</P>
</TD>
<TD>
<P>Wide range</P>
</TD>
<TD>
<P>Terbut 5mgx4 nebuliser</P>
</TD>
<TD>
<P>2 weeks /?</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>Usual meds continued</P>
</TD>
</TR>
<TR>
<TD>
<P>Guyatt 1987</P>
</TD>
<TD>
<P>27 (0)</P>
</TD>
<TD>
<P>65 (SD 7.4)</P>
</TD>
<TD>
<P>all</P>
</TD>
<TD>
<P>FEV1 &lt;70%</P>
</TD>
<TD>
<P>&lt;25%</P>
</TD>
<TD>
<P>Salbut 0.2 mgX4 MDI</P>
</TD>
<TD>
<P>2 weeks /3 days</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>No theophylline</P>
</TD>
</TR>
<TR>
<TD>
<P>Guyatt 1988</P>
</TD>
<TD>
<P>32 (1)</P>
</TD>
<TD>
<P>65 (SD 7.4)</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>FEV1 &lt;70%</P>
</TD>
<TD>
<P>&lt;35%</P>
</TD>
<TD>
<P>Salbut 0.2 mgX4 MDI</P>
</TD>
<TD>
<P>2 weeks /3 days</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>No theophylline</P>
</TD>
</TR>
<TR>
<TD>
<P>Guyatt 1989</P>
</TD>
<TD>
<P>32 (1)</P>
</TD>
<TD>
<P>65 (SD 7.4)</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>FEV1 &lt;70%</P>
</TD>
<TD>
<P>&lt;35%</P>
</TD>
<TD>
<P>Salbut 0.2 mgX4 MDI</P>
</TD>
<TD>
<P>2 weeks /3 days</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>No theophylline</P>
</TD>
</TR>
<TR>
<TD>
<P>Jaeschke 1991</P>
</TD>
<TD>
<P>32 (1)</P>
</TD>
<TD>
<P>65 (SD 7.4)</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>FEV1 &lt;70%</P>
</TD>
<TD>
<P>&lt;25%?</P>
</TD>
<TD>
<P>Salbut 0.2 mgX4 MDI</P>
</TD>
<TD>
<P>2 weeks /3 days</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>No theophylline</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Short acting beta-2 agonist vs Placebo</NAME>
<CONT_OUTCOME CHI2="0.5383809154272106" CI_END="0.06724426458913968" CI_START="-0.07558886393931705" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.004172299675088687" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="0.9696586479062334" P_Q="1.0" P_Z="0.9088374452682446" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="97" TOTAL_2="97" UNITS="" WEIGHT="100.0" Z="0.11450504767530563">
<NAME>FEV1 (L) pre-bronchodilator</NAME>
<GROUP_LABEL_1>Beta agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Beta agonist</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.5383809154272106" CI_END="0.06724426458913968" CI_START="-0.07558886393931705" DF="4.0" EFFECT_SIZE="-0.004172299675088687" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" NO="1" P_CHI2="0.9696586479062334" P_Z="0.9088374452682446" STUDIES="5" TAU2="0.0" TOTAL_1="97" TOTAL_2="97" WEIGHT="100.0" Z="0.11450504767530563">
<NAME>FEV1 pre-bronchodilator</NAME>
<CONT_DATA CI_END="0.07001519460592184" CI_START="-0.09001519460592186" EFFECT_SIZE="-0.010000000000000009" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="0.71" ORDER="147" SD_1="0.2" SD_2="0.2" SE="0.040824829046386304" STUDY_ID="STD-Hansen-1990" TOTAL_1="48" TOTAL_2="48" WEIGHT="79.66232448721233"/>
<CONT_DATA CI_END="0.2141411569160021" CI_START="-0.29414115691600173" EFFECT_SIZE="-0.039999999999999813" ESTIMABLE="YES" MEAN_1="1.86" MEAN_2="1.9" ORDER="148" SD_1="0.41" SD_2="0.29" SE="0.12966623821694426" STUDY_ID="STD-Klock-1975" TOTAL_1="15" TOTAL_2="15" WEIGHT="7.896741126805348"/>
<CONT_DATA CI_END="0.3549679789006347" CI_START="-0.3349679789006347" EFFECT_SIZE="0.010000000000000009" ESTIMABLE="YES" MEAN_1="1.03" MEAN_2="1.02" ORDER="149" SD_1="0.49" SD_2="0.44" SE="0.1760073050432039" STUDY_ID="STD-Light-1975" TOTAL_1="14" TOTAL_2="14" WEIGHT="4.285883263473111"/>
<CONT_DATA CI_END="0.3852136569713626" CI_START="-0.22521365697136247" EFFECT_SIZE="0.08000000000000007" ESTIMABLE="YES" MEAN_1="0.78" MEAN_2="0.7" ORDER="150" SD_1="0.34" SD_2="0.28" SE="0.15572411502397437" STUDY_ID="STD-Silins-1985" TOTAL_1="8" TOTAL_2="8" WEIGHT="5.475073847918374"/>
<CONT_DATA CI_END="0.5162479483144361" CI_START="-0.35624794831443596" EFFECT_SIZE="0.08000000000000007" ESTIMABLE="YES" MEAN_1="1.22" MEAN_2="1.14" ORDER="151" SD_1="0.53" SD_2="0.56" SE="0.22257957378579615" STUDY_ID="STD-Taylor-1985" TOTAL_1="12" TOTAL_2="12" WEIGHT="2.679977274590827"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.9323084819651387" CI_END="0.24526389156380252" CI_START="0.03673985160269476" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.14100187158324864" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="0.9678387317372703" P_Q="0.6145984905999079" P_Z="0.008034510504071083" Q="0.2535327747587033" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="98" TOTAL_2="98" UNITS="" WEIGHT="100.00000000000003" Z="2.650616112247329">
<NAME>FEV1 (L) post-bronchodilator</NAME>
<GROUP_LABEL_1>Beta agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Beta agonist</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.12463832628533329" CI_END="0.2821439007943201" CI_START="-0.07445638688379273" DF="1.0" EFFECT_SIZE="0.1038437569552637" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" NO="1" P_CHI2="0.7240573698601502" P_Z="0.25366097602133697" STUDIES="2" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="34.193919299927565" Z="1.1415022964612136">
<NAME>FEV1 post-bronchodilator (isoproterenol or metaproterenol))</NAME>
<CONT_DATA CI_END="0.3195893984423975" CI_START="-0.07958939844239749" EFFECT_SIZE="0.12" ESTIMABLE="YES" MEAN_1="0.77" MEAN_2="0.65" ORDER="152" SD_1="0.26" SD_2="0.19" SE="0.10183319694480775" STUDY_ID="STD-Dullinger-1986" TOTAL_1="10" TOTAL_2="10" WEIGHT="27.28835341415597"/>
<CONT_DATA CI_END="0.43675873610259663" CI_START="-0.356758736102597" EFFECT_SIZE="0.039999999999999813" ESTIMABLE="YES" MEAN_1="1.15" MEAN_2="1.11" ORDER="153" SD_1="0.56" SD_2="0.51" SE="0.2024316463119624" STUDY_ID="STD-Light-1975" TOTAL_1="14" TOTAL_2="14" WEIGHT="6.905565885771595"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.5541373809211021" CI_END="0.28883646808667296" CI_START="0.03178320720675848" DF="3.0" EFFECT_SIZE="0.16030983764671572" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" NO="2" P_CHI2="0.9068464770732626" P_Z="0.014499627297420575" STUDIES="4" TAU2="0.0" TOTAL_1="74" TOTAL_2="74" WEIGHT="65.80608070007246" Z="2.4446412940220132">
<NAME>FEV1 post bronchodilator (salbutamol or terbutaline)</NAME>
<CONT_DATA CI_END="0.32748159432155255" CI_START="-0.04748159432155277" EFFECT_SIZE="0.1399999999999999" ESTIMABLE="YES" MEAN_1="0.95" MEAN_2="0.81" ORDER="154" SD_1="0.3" SD_2="0.36" SE="0.09565563234854495" STUDY_ID="STD-Guyatt-1989" TOTAL_1="24" TOTAL_2="24" WEIGHT="30.926800536043444"/>
<CONT_DATA CI_END="0.4701607817938589" CI_START="-0.17016078179385885" EFFECT_SIZE="0.15000000000000002" ESTIMABLE="YES" MEAN_1="0.73" MEAN_2="0.58" ORDER="155" SD_1="0.41" SD_2="0.39" SE="0.16335033925074452" STUDY_ID="STD-Shah-1983" TOTAL_1="12" TOTAL_2="12" WEIGHT="10.605130227537694"/>
<CONT_DATA CI_END="0.4590904136236343" CI_START="-0.27909041362363435" EFFECT_SIZE="0.08999999999999997" ESTIMABLE="YES" MEAN_1="0.85" MEAN_2="0.76" ORDER="156" SD_1="0.41" SD_2="0.34" SE="0.18831489585266484" STUDY_ID="STD-Silins-1985" TOTAL_1="8" TOTAL_2="8" WEIGHT="7.979703204929079"/>
<CONT_DATA CI_END="0.4982892464906763" CI_START="-0.018289246490676314" EFFECT_SIZE="0.24" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="1.16" ORDER="157" SD_1="0.53" SD_2="0.49" SE="0.13178264933847197" STUDY_ID="STD-Tandon-1990" TOTAL_1="30" TOTAL_2="30" WEIGHT="16.294446731562232"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.848483838884601" CI_END="0.18838425634914888" CI_START="-0.06923913967955617" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.05957255833479635" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="0.5633881541443371" P_Q="1.0" P_Z="0.3647030469985114" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="126" TOTAL_2="126" UNITS="" WEIGHT="100.00000000000001" Z="0.9064399476366082">
<NAME>FVC (L) pre-bronchodilator</NAME>
<GROUP_LABEL_1>Beta agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Beta agonist</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.848483838884601" CI_END="0.18838425634914888" CI_START="-0.06923913967955617" DF="6.0" EFFECT_SIZE="0.05957255833479635" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.01" NO="1" P_CHI2="0.5633881541443371" P_Z="0.3647030469985114" STUDIES="7" TAU2="0.0" TOTAL_1="126" TOTAL_2="126" WEIGHT="100.00000000000001" Z="0.9064399476366082">
<NAME>FVC (pre-bronchodilator)</NAME>
<CONT_DATA CI_END="0.7414303827145703" CI_START="-0.16143038271457022" EFFECT_SIZE="0.29000000000000004" ESTIMABLE="YES" MEAN_1="2.92" MEAN_2="2.63" ORDER="158" SD_1="0.52" SD_2="0.51" SE="0.23032585612562043" STUDY_ID="STD-Dullinger-1986" TOTAL_1="10" TOTAL_2="10" WEIGHT="8.141961418940081"/>
<CONT_DATA CI_END="0.794106961444788" CI_START="-0.014106961444787736" EFFECT_SIZE="0.3900000000000001" ESTIMABLE="YES" MEAN_1="2.75" MEAN_2="2.36" ORDER="159" SD_1="0.66" SD_2="0.61" SE="0.20618080976606304" STUDY_ID="STD-Guyatt-1987" TOTAL_1="19" TOTAL_2="19" WEIGHT="10.160567057348837"/>
<CONT_DATA CI_END="0.1400303892118437" CI_START="-0.18003038921184372" EFFECT_SIZE="-0.020000000000000018" ESTIMABLE="YES" MEAN_1="1.65" MEAN_2="1.67" ORDER="160" SD_1="0.4" SD_2="0.4" SE="0.08164965809277261" STUDY_ID="STD-Hansen-1990" TOTAL_1="48" TOTAL_2="48" WEIGHT="64.78965799121569"/>
<CONT_DATA CI_END="0.5140380578073424" CI_START="-0.594038057807342" EFFECT_SIZE="-0.039999999999999813" ESTIMABLE="YES" MEAN_1="1.86" MEAN_2="1.9" ORDER="161" SD_1="0.85" SD_2="0.69" SE="0.2826776727417053" STUDY_ID="STD-Klock-1975" TOTAL_1="15" TOTAL_2="15" WEIGHT="5.40544451787216"/>
<CONT_DATA CI_END="0.6264657600653543" CI_START="-0.6064657600653538" EFFECT_SIZE="0.010000000000000231" ESTIMABLE="YES" MEAN_1="2.58" MEAN_2="2.57" ORDER="162" SD_1="0.89" SD_2="0.77" SE="0.3145291265186285" STUDY_ID="STD-Light-1975" TOTAL_1="14" TOTAL_2="14" WEIGHT="4.366090069203465"/>
<CONT_DATA CI_END="0.8666441153274453" CI_START="-0.6666441153274452" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="2.79" MEAN_2="2.69" ORDER="163" SD_1="0.84" SD_2="0.72" SE="0.3911521443121589" STUDY_ID="STD-Silins-1985" TOTAL_1="8" TOTAL_2="8" WEIGHT="2.8230787795736694"/>
<CONT_DATA CI_END="0.8102338984090423" CI_START="-0.43023389840904147" EFFECT_SIZE="0.1900000000000004" ESTIMABLE="YES" MEAN_1="2.74" MEAN_2="2.55" ORDER="164" SD_1="0.76" SD_2="0.79" SE="0.3164516814091318" STUDY_ID="STD-Taylor-1985" TOTAL_1="12" TOTAL_2="12" WEIGHT="4.313200165846097"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.3827776574005985" CI_END="0.5759161797563852" CI_START="0.02471259695292377" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.30031438835465446" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="0.7095768598568344" P_Q="0.41188145580649194" P_Z="0.03270309334605725" Q="0.6733642827658071" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="58" TOTAL_2="58" UNITS="" WEIGHT="100.0" Z="2.1357095765619234">
<NAME>FVC (L) post-bronchodilator</NAME>
<GROUP_LABEL_1>Beta agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Beta agonist</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7201022577547801" CI_START="-0.64010225775478" DF="0.0" EFFECT_SIZE="0.040000000000000036" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.01" NO="1" P_CHI2="1.0" P_Z="0.9082274195310214" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="14" WEIGHT="16.42160642060988" Z="0.11527466419596843">
<NAME>FVC (post-bronchodilator) (isoprenaline)</NAME>
<CONT_DATA CI_END="0.72010225775478" CI_START="-0.6401022577547799" EFFECT_SIZE="0.040000000000000036" ESTIMABLE="YES" MEAN_1="2.81" MEAN_2="2.77" ORDER="165" SD_1="0.99" SD_2="0.84" SE="0.34699732399132827" STUDY_ID="STD-Light-1975" TOTAL_1="14" TOTAL_2="14" WEIGHT="16.42160642060988"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.7094133746347915" CI_END="0.65292504536618" CI_START="0.04999764363569681" DF="2.0" EFFECT_SIZE="0.3514613445009384" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.02" NO="2" P_CHI2="0.7013792392863288" P_Z="0.022311462235520746" STUDIES="3" TAU2="0.0" TOTAL_1="44" TOTAL_2="44" WEIGHT="83.57839357939012" Z="2.2850232887169057">
<NAME>FVC (post-bronchodilator) (salbutamol or terbutaline)</NAME>
<CONT_DATA CI_END="0.8444554326112543" CI_START="0.055544567388746025" EFFECT_SIZE="0.4500000000000002" ESTIMABLE="YES" MEAN_1="2.7" MEAN_2="2.25" ORDER="166" SD_1="0.75" SD_2="0.64" SE="0.20125646987529783" STUDY_ID="STD-Jaeschke-1991" TOTAL_1="24" TOTAL_2="24" WEIGHT="48.816674257302296"/>
<CONT_DATA CI_END="0.8697559529644564" CI_START="-0.30975595296445635" EFFECT_SIZE="0.28" ESTIMABLE="YES" MEAN_1="2.04" MEAN_2="1.76" ORDER="167" SD_1="0.79" SD_2="0.68" SE="0.3009014235038889" STUDY_ID="STD-Shah-1983" TOTAL_1="12" TOTAL_2="12" WEIGHT="21.838329059145675"/>
<CONT_DATA CI_END="0.8666441153274453" CI_START="-0.6666441153274452" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="2.79" MEAN_2="2.69" ORDER="168" SD_1="0.84" SD_2="0.72" SE="0.3911521443121589" STUDY_ID="STD-Silins-1985" TOTAL_1="8" TOTAL_2="8" WEIGHT="12.92339026294215"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.6210325082905825" CI_END="0.23683205996349338" CI_START="-0.44658200473281146" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.10487497238465904" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" NO="5" P_CHI2="0.4446286668144114" P_Q="1.0" P_Z="0.547478977377855" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="35" TOTAL_2="35" UNITS="" WEIGHT="100.0" Z="0.601542108574857">
<NAME>FRC (L)</NAME>
<GROUP_LABEL_1>Beta agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Beta agonist</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.6210325082905825" CI_END="0.23683205996349338" CI_START="-0.44658200473281146" DF="2.0" EFFECT_SIZE="-0.10487497238465904" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.01" NO="1" P_CHI2="0.4446286668144114" P_Z="0.547478977377855" STUDIES="3" TAU2="0.0" TOTAL_1="35" TOTAL_2="35" WEIGHT="100.0" Z="0.601542108574857">
<NAME>FRC (pre-bronchodilator)</NAME>
<CONT_DATA CI_END="0.5118983556414511" CI_START="-0.3718983556414505" EFFECT_SIZE="0.07000000000000028" ESTIMABLE="YES" MEAN_1="5.07" MEAN_2="5.0" ORDER="169" SD_1="0.67" SD_2="0.56" SE="0.22546248764114474" STUDY_ID="STD-Klock-1975" TOTAL_1="15" TOTAL_2="15" WEIGHT="59.7947510916321"/>
<CONT_DATA CI_END="0.21864148598168187" CI_START="-1.0786414859816813" EFFECT_SIZE="-0.4299999999999997" ESTIMABLE="YES" MEAN_1="4.82" MEAN_2="5.25" ORDER="170" SD_1="0.71" SD_2="0.61" SE="0.3309456148674582" STUDY_ID="STD-Silins-1985" TOTAL_1="8" TOTAL_2="8" WEIGHT="27.752262166853527"/>
<CONT_DATA CI_END="0.7483161022195998" CI_START="-1.1883161022195994" EFFECT_SIZE="-0.21999999999999975" ESTIMABLE="YES" MEAN_1="4.79" MEAN_2="5.01" ORDER="171" SD_1="1.23" SD_2="1.19" SE="0.4940479059092684" STUDY_ID="STD-Taylor-1985" TOTAL_1="12" TOTAL_2="12" WEIGHT="12.452986741514371"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.05.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>FRC (post-bronchodilator)</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.025649520674582666" CI_END="0.36058188417240655" CI_START="-0.8532901529366336" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.24635413438211354" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" NO="6" P_CHI2="0.87275925103546" P_Q="1.0" P_Z="0.42629624984282166" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="20" TOTAL_2="20" UNITS="" WEIGHT="100.0" Z="0.7955455205664484">
<NAME>TLC (L)</NAME>
<GROUP_LABEL_1>Beta agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Beta agonist</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.025649520674582666" CI_END="0.36058188417240655" CI_START="-0.8532901529366336" DF="1.0" EFFECT_SIZE="-0.24635413438211354" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.01" NO="1" P_CHI2="0.87275925103546" P_Z="0.42629624984282166" STUDIES="2" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.7955455205664484">
<NAME>TLC (pre-bronchodilator)</NAME>
<CONT_DATA CI_END="0.5184999916984316" CI_START="-1.0984999916984317" EFFECT_SIZE="-0.29000000000000004" ESTIMABLE="YES" MEAN_1="6.93" MEAN_2="7.22" ORDER="172" SD_1="0.83" SD_2="0.82" SE="0.41250757568801083" STUDY_ID="STD-Silins-1985" TOTAL_1="8" TOTAL_2="8" WEIGHT="56.354134382113735"/>
<CONT_DATA CI_END="0.7286950065518695" CI_START="-1.1086950065518684" EFFECT_SIZE="-0.1899999999999995" ESTIMABLE="YES" MEAN_1="6.82" MEAN_2="7.01" ORDER="173" SD_1="1.23" SD_2="1.06" SE="0.46873055515224665" STUDY_ID="STD-Taylor-1985" TOTAL_1="12" TOTAL_2="12" WEIGHT="43.64586561788627"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.06.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>TLC (post-bronchodilator)</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.15161324005429638" CI_END="0.0752980435890524" CI_START="-0.9141108242092884" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.419406390310118" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" NO="7" P_CHI2="0.696998594229353" P_Q="1.0" P_Z="0.09658467620663862" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="20" TOTAL_2="20" UNITS="" WEIGHT="100.0" Z="1.6616415046349124">
<NAME>RV (L)</NAME>
<GROUP_LABEL_1>Beta agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Beta agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.15161324005429638" CI_END="0.0752980435890524" CI_START="-0.9141108242092884" DF="1.0" EFFECT_SIZE="-0.419406390310118" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" NO="1" P_CHI2="0.696998594229353" P_Z="0.09658467620663862" STUDIES="2" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.6616415046349124">
<NAME>RV (pre-bronchodilator)</NAME>
<CONT_DATA CI_END="0.1011714607665547" CI_START="-1.0611714607665546" EFFECT_SIZE="-0.48" ESTIMABLE="YES" MEAN_1="3.97" MEAN_2="4.45" ORDER="174" SD_1="0.65" SD_2="0.53" SE="0.29652150006365474" STUDY_ID="STD-Silins-1985" TOTAL_1="8" TOTAL_2="8" WEIGHT="72.45745014096272"/>
<CONT_DATA CI_END="0.6826353682009763" CI_START="-1.2026353682009767" EFFECT_SIZE="-0.26000000000000023" ESTIMABLE="YES" MEAN_1="3.86" MEAN_2="4.12" ORDER="175" SD_1="1.09" SD_2="1.26" SE="0.4809452498292642" STUDY_ID="STD-Taylor-1985" TOTAL_1="12" TOTAL_2="12" WEIGHT="27.542549859037273"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.07.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>RV (post-bronchodilator)</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.3162730148341995" CI_END="15.068470961329826" CI_START="-2.0594950085705044" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="MD" EFFECT_SIZE="6.504487976379661" ESTIMABLE="YES" I2="0.0" I2_Q="61.33567693889356" ID="CMP-001.08" NO="8" P_CHI2="0.6513512984712129" P_Q="0.10778792885830568" P_Z="0.13658605228660675" Q="2.58636365731676" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="129" TOTAL_2="129" UNITS="" WEIGHT="200.0" Z="1.4886253503751141">
<NAME>PEFR - morning (L/min)</NAME>
<GROUP_LABEL_1>Beta agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Beta agonist</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.10606438964409629" CI_END="13.291957646117922" CI_START="-4.640347905015516" DF="1.0" EFFECT_SIZE="4.325804870551203" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.01" NO="1" P_CHI2="0.7446700805385731" P_Z="0.34435108021524896" STUDIES="2" TAU2="0.0" TOTAL_1="67" TOTAL_2="67" WEIGHT="100.0" Z="0.9456030878185007">
<NAME>PEFR - morning (pre-bronchodilator)</NAME>
<CONT_DATA CI_END="19.487360223396003" CI_START="-7.487360223396005" EFFECT_SIZE="6.0" ESTIMABLE="YES" MEAN_1="190.0" MEAN_2="184.0" ORDER="176" SD_1="21.21" SD_2="21.21" SE="6.881432684366947" STUDY_ID="STD-Guyatt-1987" TOTAL_1="19" TOTAL_2="19" WEIGHT="44.19349568504011"/>
<CONT_DATA CI_END="15.002279190888276" CI_START="-9.002279190888276" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="182.0" MEAN_2="179.0" ORDER="177" SD_1="30.0" SD_2="30.0" SE="6.123724356957945" STUDY_ID="STD-Hansen-1990" TOTAL_1="48" TOTAL_2="48" WEIGHT="55.80650431495989"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.6238449678733432" CI_END="58.088324321517604" CI_START="0.2501516104409305" DF="3.0" EFFECT_SIZE="29.169237965979267" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.02" NO="2" P_CHI2="0.890952577982602" P_Z="0.048050925207866024" STUDIES="4" TAU2="0.0" TOTAL_1="62" TOTAL_2="62" WEIGHT="100.00000000000001" Z="1.9769177755800336">
<NAME>PEFR - morning (post-bronchodilator)</NAME>
<CONT_DATA CI_END="65.6168606407267" CI_START="-35.6168606407267" EFFECT_SIZE="15.0" ESTIMABLE="YES" MEAN_1="208.0" MEAN_2="193.0" ORDER="178" SD_1="81.33" SD_2="77.83" SE="25.825403446178623" STUDY_ID="STD-Guyatt-1987" TOTAL_1="19" TOTAL_2="19" WEIGHT="32.64214762414935"/>
<CONT_DATA CI_END="109.31287276295257" CI_START="-69.31287276295257" EFFECT_SIZE="20.0" ESTIMABLE="YES" MEAN_1="218.0" MEAN_2="198.0" ORDER="179" SD_1="96.0" SD_2="86.0" SE="45.56862956025779" STUDY_ID="STD-Silins-1985" TOTAL_1="8" TOTAL_2="8" WEIGHT="10.484338125953483"/>
<CONT_DATA CI_END="86.41335992886903" CI_START="-14.213359928869046" EFFECT_SIZE="36.099999999999994" ESTIMABLE="YES" MEAN_1="286.7" MEAN_2="250.6" ORDER="180" SD_1="102.86" SD_2="95.86" SE="25.67055329880263" STUDY_ID="STD-Tandon-1990" TOTAL_1="30" TOTAL_2="30" WEIGHT="33.037143917240826"/>
<CONT_DATA CI_END="102.23310596256371" CI_START="-16.233105962563712" EFFECT_SIZE="43.0" ESTIMABLE="YES" MEAN_1="199.0" MEAN_2="156.0" ORDER="181" SD_1="45.14" SD_2="50.29" SE="30.22152775754396" STUDY_ID="STD-Wilson-1980" TOTAL_1="5" TOTAL_2="5" WEIGHT="23.83637033265636"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.6518633346432354" CI_END="16.51381251368918" CI_START="-0.9993369305102258" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="MD" EFFECT_SIZE="7.7572377915894775" ESTIMABLE="YES" I2="0.0" I2_Q="66.1854145708933" ID="CMP-001.09" NO="9" P_CHI2="0.4551658596741782" P_Q="0.08549056003427913" P_Z="0.08251350764121275" Q="2.9573037412998318" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="110" TOTAL_2="110" UNITS="" WEIGHT="200.0" Z="1.7362846973322832">
<NAME>PEFR - evening (L/min)</NAME>
<GROUP_LABEL_1>Beta agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Beta agonist</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.1836138860900522" CI_END="14.780159176029414" CI_START="-3.3373988118409343" DF="1.0" EFFECT_SIZE="5.72138018209424" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.01" NO="1" P_CHI2="0.668285750288231" P_Z="0.21575985590380065" STUDIES="2" TAU2="0.0" TOTAL_1="67" TOTAL_2="67" WEIGHT="100.0" Z="1.2378819602811224">
<NAME>PEFR - evening (pre-bronchodilator)</NAME>
<CONT_DATA CI_END="21.808969190752318" CI_START="-5.808969190752318" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="215.0" MEAN_2="207.0" ORDER="182" SD_1="22.21" SD_2="21.21" SE="7.045521907379781" STUDY_ID="STD-Guyatt-1987" TOTAL_1="19" TOTAL_2="19" WEIGHT="43.03450455235598"/>
<CONT_DATA CI_END="16.002279190888274" CI_START="-8.002279190888276" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="187.0" MEAN_2="183.0" ORDER="183" SD_1="30.0" SD_2="30.0" SE="6.123724356957945" STUDY_ID="STD-Hansen-1990" TOTAL_1="48" TOTAL_2="48" WEIGHT="56.96549544764402"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.5109457072533513" CI_END="70.9387262105136" CI_START="2.565449460889539" DF="2.0" EFFECT_SIZE="36.752087835701566" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.02" NO="2" P_CHI2="0.7745501737769366" P_Z="0.03511372204173552" STUDIES="3" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="2.1070445044897976">
<NAME>PEFR - evening (post-bronchodilator)</NAME>
<CONT_DATA CI_END="115.09737540576758" CI_START="-79.09737540576758" EFFECT_SIZE="18.0" ESTIMABLE="YES" MEAN_1="233.0" MEAN_2="215.0" ORDER="184" SD_1="103.0" SD_2="95.0" SE="49.540387564087546" STUDY_ID="STD-Silins-1985" TOTAL_1="8" TOTAL_2="8" WEIGHT="12.396463739069947"/>
<CONT_DATA CI_END="79.31335992886903" CI_START="-21.31335992886904" EFFECT_SIZE="29.0" ESTIMABLE="YES" MEAN_1="289.0" MEAN_2="260.0" ORDER="185" SD_1="102.86" SD_2="95.86" SE="25.67055329880263" STUDY_ID="STD-Tandon-1990" TOTAL_1="30" TOTAL_2="30" WEIGHT="46.16854150184254"/>
<CONT_DATA CI_END="104.10956617729761" CI_START="-2.1095661772976086" EFFECT_SIZE="51.0" ESTIMABLE="YES" MEAN_1="201.0" MEAN_2="150.0" ORDER="186" SD_1="34.73" SD_2="49.65" SE="27.097215355087688" STUDY_ID="STD-Wilson-1980" TOTAL_1="5" TOTAL_2="5" WEIGHT="41.434994759087516"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="13.656437449930456" CI_START="-14.056437449930447" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.19999999999999574" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.10" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.9774311911623578" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="14" UNITS="" WEIGHT="100.0" Z="0.02828958008322478">
<NAME>SGaw (L/sec/cm H2O/L)</NAME>
<GROUP_LABEL_1>Beta agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Beta agonist</GRAPH_LABEL_2>
<CONT_DATA CI_END="13.656437449930456" CI_START="-14.056437449930447" EFFECT_SIZE="-0.19999999999999574" ESTIMABLE="YES" MEAN_1="51.2" MEAN_2="51.4" ORDER="187" SD_1="19.73" SD_2="17.62" SE="7.069740851989252" STUDY_ID="STD-Light-1975" TOTAL_1="14" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.014820976610505576" CI_START="-0.5748209766105061" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.28000000000000025" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.11" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.06268285265886374" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" UNITS="" WEIGHT="100.0" Z="1.8614344270225842">
<NAME>Raw (cm H2O/L/sec)</NAME>
<GROUP_LABEL_1>Beta agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Beta agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.014820976610505576" CI_START="-0.5748209766105061" EFFECT_SIZE="-0.28000000000000025" ESTIMABLE="YES" MEAN_1="2.57" MEAN_2="2.85" ORDER="188" SD_1="0.45" SD_2="0.37" SE="0.15042162965034872" STUDY_ID="STD-Klock-1975" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.1132871480030446" CI_START="-1.1132871480030446" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.12" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="0.0">
<NAME>Progressive Cycle Ergometry or PCE (min)</NAME>
<GROUP_LABEL_1>Beta agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Beta agonist</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.1132871480030446" CI_START="-1.1132871480030446" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="4.3" MEAN_2="4.3" ORDER="189" SD_1="1.1" SD_2="1.42" SE="0.5680140843324222" STUDY_ID="STD-Dullinger-1986" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.9831704408481081" CI_END="0.4688867226963993" CI_START="-0.10600913636273637" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.18143879316683145" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.13" NO="13" P_CHI2="0.5759071116014073" P_Q="0.5998838619258509" P_Z="0.2160349180186022" Q="0.2751711815778204" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="94" TOTAL_2="94" UNITS="" WEIGHT="100.0" Z="1.23714058607899">
<NAME>Distance Walked (m)</NAME>
<GROUP_LABEL_1>Beta agonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Beta agonist</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.7079992592702877" CI_END="0.4589254180459814" CI_START="-0.1487081667572374" DF="2.0" EFFECT_SIZE="0.15510862564437203" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.01" NO="1" P_CHI2="0.425709154326971" P_Z="0.31700713032262395" STUDIES="3" TAU2="0.0" TOTAL_1="84" TOTAL_2="84" WEIGHT="89.51479491863475" Z="1.0006271133052242">
<NAME>6MW</NAME>
<CONT_DATA CI_END="0.9466956843641731" CI_START="-0.1957020705586371" EFFECT_SIZE="0.375496806902768" ESTIMABLE="YES" MEAN_1="434.0" MEAN_2="392.0" ORDER="190" SD_1="112.0" SD_2="108.0" SE="0.2914333538610653" STUDY_ID="STD-Guyatt-1987" TOTAL_1="24" TOTAL_2="24" WEIGHT="25.324663244887955"/>
<CONT_DATA CI_END="0.38204809174174154" CI_START="-0.4181208190144688" EFFECT_SIZE="-0.018036363636363635" ESTIMABLE="YES" MEAN_1="377.0" MEAN_2="379.0" ORDER="191" SD_1="110.0" SD_2="110.0" SE="0.20412847304028048" STUDY_ID="STD-Hansen-1990" TOTAL_1="48" TOTAL_2="48" WEIGHT="51.6196450349017"/>
<CONT_DATA CI_END="1.2328599689224526" CI_START="-0.38862577634055856" EFFECT_SIZE="0.422117096290947" ESTIMABLE="YES" MEAN_1="405.0" MEAN_2="370.0" ORDER="192" SD_1="83.0" SD_2="77.0" SE="0.4136519237223448" STUDY_ID="STD-Shah-1983" TOTAL_1="12" TOTAL_2="12" WEIGHT="12.570486638845091"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.293935158805021" CI_START="-0.481483238415631" DF="0.0" EFFECT_SIZE="0.4062259601946949" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.02" NO="2" P_CHI2="1.0" P_Z="0.36977116507532093" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="10.485205081365253" Z="0.8969021080475513">
<NAME>12MW</NAME>
<CONT_DATA CI_END="1.293935158805021" CI_START="-0.481483238415631" EFFECT_SIZE="0.4062259601946949" ESTIMABLE="YES" MEAN_1="802.0" MEAN_2="764.0" ORDER="193" SD_1="76.5" SD_2="101.0" SE="0.4529211789667886" STUDY_ID="STD-Dullinger-1986" TOTAL_1="10" TOTAL_2="10" WEIGHT="10.485205081365253"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.317899426578612" CI_END="0.6373477575017992" CI_START="-6.011556453542343" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.687104348020272" ESTIMABLE="YES" I2="0.0" I2_Q="21.826911341468342" ID="CMP-001.14" NO="14" P_CHI2="0.7248872669473356" P_Q="0.25804559646898306" P_Z="0.11314611119201438" Q="1.279212600090686" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="26" UNITS="" WEIGHT="100.0" Z="1.584209240395613">
<NAME>Rescue Beta-2 usage (per week)</NAME>
<GROUP_LABEL_1>Beta agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Beta agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.001164954682549603" CI_END="3.775543495887419" CI_START="-25.750540820057836" DF="1.0" EFFECT_SIZE="-10.987498662085208" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.01" NO="1" P_CHI2="0.9727723460561" P_Z="0.1446429947956259" STUDIES="2" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="5.070939641512744" Z="1.4587170738545399">
<NAME>Daytime usage</NAME>
<CONT_DATA CI_END="5.014670839918603" CI_START="-27.214670839918604" EFFECT_SIZE="-11.1" ESTIMABLE="YES" MEAN_1="11.9" MEAN_2="23.0" ORDER="194" SD_1="15.2" SD_2="17.6" SE="8.221921916437786" STUDY_ID="STD-Silins-1985" TOTAL_1="8" TOTAL_2="8" WEIGHT="4.255957507005124"/>
<CONT_DATA CI_END="26.425278188031637" CI_START="-47.22527818803164" EFFECT_SIZE="-10.400000000000002" ESTIMABLE="YES" MEAN_1="28.8" MEAN_2="39.2" ORDER="195" SD_1="30.1" SD_2="29.31" SE="18.788752486527677" STUDY_ID="STD-Wilson-1980" TOTAL_1="5" TOTAL_2="5" WEIGHT="0.814982134507621"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.03752187180537637" CI_END="1.168377876076589" CI_START="-5.655802305878144" DF="1.0" EFFECT_SIZE="-2.2437122149007775" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.02" NO="2" P_CHI2="0.8464064584347846" P_Z="0.19745810496602098" STUDIES="2" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="94.92906035848726" Z="1.288827380175786">
<NAME>Nighttime usage</NAME>
<CONT_DATA CI_END="1.78567089105589" CI_START="-6.78567089105589" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="4.7" ORDER="196" SD_1="3.9" SD_2="4.8" SE="2.1866069605669876" STUDY_ID="STD-Silins-1985" TOTAL_1="8" TOTAL_2="8" WEIGHT="60.17311947159141"/>
<CONT_DATA CI_END="3.8390449391667234" CI_START="-7.439044939166723" EFFECT_SIZE="-1.7999999999999998" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="4.8" ORDER="197" SD_1="3.69" SD_2="5.27" SE="2.8771166121657283" STUDY_ID="STD-Wilson-1980" TOTAL_1="5" TOTAL_2="5" WEIGHT="34.75594088689585"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="8.452789031642311" CI_START="-6.852789031642317" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.7999999999999972" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.15" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.8376589625039992" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="14" UNITS="" WEIGHT="100.0" Z="0.2048888557033103">
<NAME>PaO2 (mmHg)</NAME>
<GROUP_LABEL_1>Beta agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Beta agonist</GRAPH_LABEL_2>
<CONT_DATA CI_END="8.452789031642311" CI_START="-6.852789031642317" EFFECT_SIZE="0.7999999999999972" ESTIMABLE="YES" MEAN_1="67.5" MEAN_2="66.7" ORDER="198" SD_1="10.43" SD_2="10.23" SE="3.9045559469492996" STUDY_ID="STD-Light-1975" TOTAL_1="14" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.7549060494810589" CI_END="0.3991002224920046" CI_START="-0.9284776331725284" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.2646887053402619" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.16" NO="16" P_CHI2="0.68560556311635" P_Q="0.68560556311635" P_Z="0.43448254827984445" Q="0.7549060494810589" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="18" TOTAL_2="18" UNITS="" WEIGHT="300.0" Z="0.7815441141442768">
<NAME>Sputum Production</NAME>
<GROUP_LABEL_1>Beta agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Beta agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6118713287560333" CI_START="-1.9850464701627932" DF="0.0" EFFECT_SIZE="-0.68658757070338" ESTIMABLE="YES" I2="0.0" ID="CMP-001.16.01" NO="1" P_CHI2="1.0" P_Z="0.3000284759309325" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0" Z="1.0363723575476451">
<NAME>Morning Sputum Production</NAME>
<CONT_DATA CI_END="0.6118713287560333" CI_START="-1.9850464701627932" EFFECT_SIZE="-0.68658757070338" ESTIMABLE="YES" MEAN_1="9.8" MEAN_2="13.6" ORDER="199" SD_1="5.89" SD_2="3.91" SE="0.6624912037677688" STUDY_ID="STD-Wilson-1980" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9103437275222375" CI_START="-1.5989654907548918" DF="0.0" EFFECT_SIZE="-0.3443108816163272" ESTIMABLE="YES" I2="0.0" ID="CMP-001.16.02" NO="2" P_CHI2="1.0" P_Z="0.5906690855726278" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0" Z="0.5378666945770622">
<NAME>Evening Sputum Production</NAME>
<CONT_DATA CI_END="0.9103437275222375" CI_START="-1.5989654907548918" EFFECT_SIZE="-0.3443108816163272" ESTIMABLE="YES" MEAN_1="6.2" MEAN_2="9.2" ORDER="200" SD_1="7.22" SD_2="8.47" SE="0.6401416653750375" STUDY_ID="STD-Wilson-1980" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0042641741057998" CI_START="-0.9557952562435221" DF="0.0" EFFECT_SIZE="0.024234458931138854" ESTIMABLE="YES" I2="0.0" ID="CMP-001.16.03" NO="3" P_CHI2="1.0" P_Z="0.9613444162327391" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0" Z="0.04846655765063409">
<NAME>Daily Sputum Production</NAME>
<CONT_DATA CI_END="1.0042641741057998" CI_START="-0.9557952562435221" EFFECT_SIZE="0.024234458931138854" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="4.9" ORDER="201" SD_1="3.8" SD_2="4.0" SE="0.5000243488681477" STUDY_ID="STD-Silins-1985" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.47243275386507E-4" CI_END="0.25592319460140933" CI_START="-1.573988328673079" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.6590325670358348" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.17" NO="17" P_CHI2="0.9797032278759457" P_Q="0.9797032278759457" P_Z="0.15802638633738045" Q="6.47243275386507E-4" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="200.0" Z="1.4117404908384328">
<NAME>Wheeze</NAME>
<GROUP_LABEL_1>Beta agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Beta agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6448385030491343" CI_START="-1.9392210724494783" DF="0.0" EFFECT_SIZE="-0.6471912847001721" ESTIMABLE="YES" I2="0.0" ID="CMP-001.17.01" NO="1" P_CHI2="1.0" P_Z="0.32621489051946173" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0" Z="0.9817665359946551">
<NAME>Morning Wheeze</NAME>
<CONT_DATA CI_END="0.6448385030491343" CI_START="-1.9392210724494783" EFFECT_SIZE="-0.6471912847001721" ESTIMABLE="YES" MEAN_1="21.0" MEAN_2="27.2" ORDER="202" SD_1="9.11" SD_2="8.17" SE="0.6592109844572004" STUDY_ID="STD-Wilson-1980" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6249201877881968" CI_START="-1.9668086710782995" DF="0.0" EFFECT_SIZE="-0.6709442416450514" ESTIMABLE="YES" I2="0.0" ID="CMP-001.17.02" NO="2" P_CHI2="1.0" P_Z="0.3102073224052836" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0" Z="1.0147871331216125">
<NAME>Evening Wheeze</NAME>
<CONT_DATA CI_END="0.6249201877881968" CI_START="-1.9668086710782995" EFFECT_SIZE="-0.6709442416450514" ESTIMABLE="YES" MEAN_1="20.4" MEAN_2="27.8" ORDER="203" SD_1="10.6" SD_2="9.28" SE="0.6611674702468318" STUDY_ID="STD-Wilson-1980" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.17.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Daily Wheeze</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.9611862170119034" CI_START="-0.9988353571910231" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.018824570089559844" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.18" NO="18" P_CHI2="1.0" P_Q="1.0" P_Z="0.9699683094775943" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="8" TOTAL_2="8" UNITS="" WEIGHT="100.0" Z="0.03764803396614791">
<NAME>Cough</NAME>
<GROUP_LABEL_1>Beta agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Beta agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9611862170119034" CI_START="-0.9988353571910231" EFFECT_SIZE="-0.018824570089559844" ESTIMABLE="YES" MEAN_1="5.9" MEAN_2="6.0" ORDER="204" SD_1="4.1" SD_2="5.8" SE="0.5000146915104886" STUDY_ID="STD-Silins-1985" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="17.147502452998896" CI_END="-0.7821405869878826" CI_START="-1.3360553576526264" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-1.0590979723202545" ESTIMABLE="YES" I2="59.17772853984469" I2_Q="81.02600310290642" ID="CMP-001.19" NO="19" P_CHI2="0.01646943873559137" P_Q="0.005141713630784861" P_Z="6.630150439290395E-14" Q="10.540741683721667" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="120" TOTAL_2="120" UNITS="" WEIGHT="300.0" Z="7.494993785256791">
<NAME>Breathlessness</NAME>
<GROUP_LABEL_1>Beta agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Beta agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.5821591604306917" CI_END="0.47582219236490614" CI_START="-1.0910538242537813" DF="1.0" EFFECT_SIZE="-0.3076158159444376" ESTIMABLE="YES" I2="0.0" ID="CMP-001.19.01" NO="1" P_CHI2="0.44546737766351296" P_Z="0.44155082266146795" STUDIES="2" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0" Z="0.7695770615304843">
<NAME>Morning Breathlessness</NAME>
<CONT_DATA CI_END="0.9023649414236244" CI_START="-1.0585904105441533" EFFECT_SIZE="-0.07811273456026442" ESTIMABLE="YES" MEAN_1="9.8" MEAN_2="10.3" ORDER="205" SD_1="5.9" SD_2="6.2" SE="0.5002529045011906" STUDY_ID="STD-Silins-1985" TOTAL_1="8" TOTAL_2="8" WEIGHT="63.84602374262546"/>
<CONT_DATA CI_END="0.5900403514983245" CI_START="-2.015852765912928" EFFECT_SIZE="-0.7129062072073017" ESTIMABLE="YES" MEAN_1="23.8" MEAN_2="30.2" ORDER="206" SD_1="7.4" SD_2="8.76" SE="0.664780867905279" STUDY_ID="STD-Wilson-1980" TOTAL_1="5" TOTAL_2="5" WEIGHT="36.15397625737454"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.005967281549116804" CI_END="0.5346896438811585" CI_START="-1.010627484291355" DF="1.0" EFFECT_SIZE="-0.2379689202050983" ESTIMABLE="YES" I2="0.0" ID="CMP-001.19.02" NO="2" P_CHI2="0.938426112935582" P_Z="0.5460805224198242" STUDIES="2" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.00000000000001" Z="0.6036437499317102">
<NAME>Evening Breathlessness</NAME>
<CONT_DATA CI_END="0.7234656643795243" CI_START="-1.2476295589317292" EFFECT_SIZE="-0.2620819472761024" ESTIMABLE="YES" MEAN_1="5.4" MEAN_2="7.2" ORDER="207" SD_1="5.7" SD_2="7.2" SE="0.5028396539066536" STUDY_ID="STD-Silins-1985" TOTAL_1="8" TOTAL_2="8" WEIGHT="61.46388755357929"/>
<CONT_DATA CI_END="1.0451590245811395" CI_START="-1.4441778251411568" EFFECT_SIZE="-0.19950940028000866" ESTIMABLE="YES" MEAN_1="23.6" MEAN_2="26.0" ORDER="208" SD_1="9.61" SD_2="11.99" SE="0.6350465797733702" STUDY_ID="STD-Wilson-1980" TOTAL_1="5" TOTAL_2="5" WEIGHT="38.536112446420724"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="6.018634327297422" CI_END="-1.0056767474066086" CI_START="-1.6467618821259806" DF="3.0" EFFECT_SIZE="-1.3262193147662946" ESTIMABLE="YES" I2="50.154805278773175" ID="CMP-001.19.03" NO="3" P_CHI2="0.11070719023139519" P_Z="5.095633510901329E-16" STUDIES="4" TAU2="0.0" TOTAL_1="94" TOTAL_2="94" WEIGHT="100.0" Z="8.109194713058386">
<NAME>Daily Breathlessness</NAME>
<CONT_DATA CI_END="0.5135189302319434" CI_START="-1.2583490582956214" EFFECT_SIZE="-0.37241506403183905" ESTIMABLE="YES" MEAN_1="41.3" MEAN_2="46.7" ORDER="209" SD_1="12.4" SD_2="15.23" SE="0.4520154458203909" STUDY_ID="STD-Dullinger-1986" TOTAL_1="10" TOTAL_2="10" WEIGHT="13.09087540451626"/>
<CONT_DATA CI_END="-0.6959722883909442" CI_START="-1.9557411592085954" EFFECT_SIZE="-1.3258567237997698" ESTIMABLE="YES" MEAN_1="10.6" MEAN_2="13.4" ORDER="210" SD_1="2.29" SD_2="1.84" SE="0.3213755152529708" STUDY_ID="STD-Guyatt-1989" TOTAL_1="24" TOTAL_2="24" WEIGHT="25.8970126051006"/>
<CONT_DATA CI_END="-1.1533711393128687" CI_START="-2.0798414233575526" EFFECT_SIZE="-1.6166062813352107" ESTIMABLE="YES" MEAN_1="47.0" MEAN_2="56.0" ORDER="211" SD_1="6.0" SD_2="5.0" SE="0.2363488031802021" STUDY_ID="STD-Hansen-1990" TOTAL_1="48" TOTAL_2="48" WEIGHT="47.88157473787485"/>
<CONT_DATA CI_END="-0.3343429352378129" CI_START="-2.103532864748427" EFFECT_SIZE="-1.21893789999312" ESTIMABLE="YES" MEAN_1="40.0" MEAN_2="49.0" ORDER="212" SD_1="6.89" SD_2="7.36" SE="0.4513322549459476" STUDY_ID="STD-Shah-1983" TOTAL_1="12" TOTAL_2="12" WEIGHT="13.13053725250829"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="4.680993337722751" CI_END="0.7265905512742064" CI_START="0.3295871038913432" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.48936170212765956" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="46" I2="14.54805184691945" I2_Q="0.0" ID="CMP-001.20" LOG_CI_END="-0.13871025408705945" LOG_CI_START="-0.48202978974918975" LOG_EFFECT_SIZE="-0.3103700219181246" METHOD="MH" NO="20" P_CHI2="0.321622568432135" P_Q="0.0" P_Z="3.9452476240530376E-4" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="99" TOTAL_2="99" WEIGHT="100.0" Z="3.5437194895841237">
<NAME>Dropouts or Study Treatment interupted due to worsening symptoms</NAME>
<GROUP_LABEL_1>Beta agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Beta agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2528199209772994" CI_START="0.06515912757640739" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.09788865044641205" LOG_CI_START="-1.1860247391469634" LOG_EFFECT_SIZE="-0.5440680443502757" ORDER="213" O_E="0.0" SE="0.754177080520927" STUDY_ID="STD-Guyatt-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.5687830687830688" WEIGHT="14.893617021276595"/>
<DICH_DATA CI_END="2.3858386537426313" CI_START="0.008553874015450344" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3776410704497642" LOG_CI_START="-2.0678371504782778" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="214" O_E="0.0" SE="1.4364860122855576" STUDY_ID="STD-Silins-1985" TOTAL_1="8" TOTAL_2="8" VAR="2.0634920634920633" WEIGHT="7.446808510638298"/>
<DICH_DATA CI_END="0.8437349044601603" CI_START="0.3226270701708257" EFFECT_SIZE="0.5217391304347826" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="23" LOG_CI_END="-0.07379398419742278" LOG_CI_START="-0.49129919574251335" LOG_EFFECT_SIZE="-0.28254658996996806" ORDER="215" O_E="0.0" SE="0.24524462794571444" STUDY_ID="STD-Tandon-1990" TOTAL_1="30" TOTAL_2="30" VAR="0.0601449275362319" WEIGHT="48.93617021276596"/>
<DICH_DATA CI_END="1.9282567330113038" CI_START="0.40976050712718637" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.2851648564896628" LOG_CI_START="-0.3874699013844254" LOG_EFFECT_SIZE="-0.05115252244738131" ORDER="216" O_E="0.0" SE="0.3951089863709899" STUDY_ID="STD-Taylor-1985" TOTAL_1="25" TOTAL_2="25" VAR="0.1561111111111111" WEIGHT="19.148936170212764"/>
<DICH_DATA CI_END="1.8038792123445453" CI_START="0.006843961019041678" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.25620745384423804" LOG_CI_START="-2.164692472722888" LOG_EFFECT_SIZE="-0.9542425094393249" ORDER="217" O_E="0.0" SE="1.422048600513436" STUDY_ID="STD-Wilson-1980" TOTAL_1="9" TOTAL_2="9" VAR="2.022222222222222" WEIGHT="9.574468085106382"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.910001953502119" CI_END="17.612533284844826" CI_START="4.638087146964943" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="9.038167084864666" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="7" I2="49.23859545896977" I2_Q="0.0" ID="CMP-001.21" LOG_CI_END="1.2458218268646537" LOG_CI_START="0.6663389045198257" LOG_EFFECT_SIZE="0.9560803656922398" METHOD="PETO" NO="21" P_CHI2="0.11607211316304245" P_Q="1.0" P_Z="9.968263396367534E-11" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="79" TOTAL_2="79" WEIGHT="100.0" Z="6.46743160436952">
<NAME>Patients preference for active treatment over placebo</NAME>
<GROUP_LABEL_1>Beta agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Beta agonist</GRAPH_LABEL_2>
<DICH_DATA CI_END="19.7566806304216" CI_START="3.2947572134147314" EFFECT_SIZE="8.0680521825415" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="3" LOG_CI_END="1.2957139794729362" LOG_CI_START="0.5178234174856977" LOG_EFFECT_SIZE="0.9067686984793168" ORDER="218" O_E="10.0" SE="0.4569367667316877" STUDY_ID="STD-Hansen-1990" TOTAL_1="48" TOTAL_2="48" VAR="4.7894736842105265" WEIGHT="55.493776231301794"/>
<DICH_DATA CI_END="12.243434703807782" CI_START="0.5432134139828287" EFFECT_SIZE="2.57891410565208" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="1.08790326941562" LOG_CI_START="-0.2650295142305112" LOG_EFFECT_SIZE="0.4114368775925544" ORDER="219" O_E="1.5" SE="0.7947194142390264" STUDY_ID="STD-Light-1975" TOTAL_1="14" TOTAL_2="14" VAR="1.5833333333333333" WEIGHT="18.34546998122706"/>
<DICH_DATA CI_END="111.0773680332245" CI_START="2.4962086285677803" EFFECT_SIZE="16.651494963610144" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="2.0456255806371932" LOG_CI_START="0.39728088006859824" LOG_EFFECT_SIZE="1.2214532303528958" ORDER="220" O_E="3.0" SE="0.9682458365518543" STUDY_ID="STD-Silins-1985" TOTAL_1="8" TOTAL_2="8" VAR="1.0666666666666667" WEIGHT="12.359053461037176"/>
<DICH_DATA CI_END="263.3769668980198" CI_START="7.2570195584523605" EFFECT_SIZE="43.71878086160215" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="2.4205777919375304" LOG_CI_START="0.8607582935537053" LOG_EFFECT_SIZE="1.640668042745618" ORDER="221" O_E="4.5" SE="0.9162456945817024" STUDY_ID="STD-Wilson-1980" TOTAL_1="9" TOTAL_2="9" VAR="1.1911764705882353" WEIGHT="13.801700326433979"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.9323084819651387" CI_END="0.24526389156380252" CI_START="0.03673985160269477" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.14100187158324864" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.22" NO="22" P_CHI2="0.9678387317372703" P_Q="1.0" P_Z="0.008034510504071073" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="98" TOTAL_2="98" UNITS="" WEIGHT="100.0" Z="2.6506161122473295">
<NAME>FEV1 (L) post-bronchodilator</NAME>
<GROUP_LABEL_1>Beta agonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Beta agonist</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.3195893984423975" CI_START="-0.07958939844239749" EFFECT_SIZE="0.12" ESTIMABLE="YES" MEAN_1="0.77" MEAN_2="0.65" ORDER="222" SD_1="0.26" SD_2="0.19" SE="0.10183319694480775" STUDY_ID="STD-Dullinger-1986" TOTAL_1="10" TOTAL_2="10" WEIGHT="27.288353414155967"/>
<CONT_DATA CI_END="0.32748159432155255" CI_START="-0.04748159432155277" EFFECT_SIZE="0.1399999999999999" ESTIMABLE="YES" MEAN_1="0.95" MEAN_2="0.81" ORDER="223" SD_1="0.3" SD_2="0.36" SE="0.09565563234854495" STUDY_ID="STD-Guyatt-1989" TOTAL_1="24" TOTAL_2="24" WEIGHT="30.926800536043437"/>
<CONT_DATA CI_END="0.43675873610259663" CI_START="-0.356758736102597" EFFECT_SIZE="0.039999999999999813" ESTIMABLE="YES" MEAN_1="1.15" MEAN_2="1.11" ORDER="224" SD_1="0.56" SD_2="0.51" SE="0.2024316463119624" STUDY_ID="STD-Light-1975" TOTAL_1="14" TOTAL_2="14" WEIGHT="6.905565885771593"/>
<CONT_DATA CI_END="0.4701607817938589" CI_START="-0.17016078179385885" EFFECT_SIZE="0.15000000000000002" ESTIMABLE="YES" MEAN_1="0.73" MEAN_2="0.58" ORDER="225" SD_1="0.41" SD_2="0.39" SE="0.16335033925074452" STUDY_ID="STD-Shah-1983" TOTAL_1="12" TOTAL_2="12" WEIGHT="10.605130227537693"/>
<CONT_DATA CI_END="0.4590904136236343" CI_START="-0.27909041362363435" EFFECT_SIZE="0.08999999999999997" ESTIMABLE="YES" MEAN_1="0.85" MEAN_2="0.76" ORDER="226" SD_1="0.41" SD_2="0.34" SE="0.18831489585266484" STUDY_ID="STD-Silins-1985" TOTAL_1="8" TOTAL_2="8" WEIGHT="7.979703204929077"/>
<CONT_DATA CI_END="0.4982892464906763" CI_START="-0.018289246490676314" EFFECT_SIZE="0.24" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="1.16" ORDER="227" SD_1="0.53" SD_2="0.49" SE="0.13178264933847197" STUDY_ID="STD-Tandon-1990" TOTAL_1="30" TOTAL_2="30" WEIGHT="16.29444673156223"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.3827776574005985" CI_END="0.5759161797563852" CI_START="0.02471259695292377" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.30031438835465446" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.23" NO="23" P_CHI2="0.7095768598568344" P_Q="1.0" P_Z="0.03270309334605725" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="58" TOTAL_2="58" UNITS="" WEIGHT="100.0" Z="2.1357095765619234">
<NAME>FVC (L) post-bronchodilator</NAME>
<GROUP_LABEL_1>Beta agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Beta agonist</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.8444554326112543" CI_START="0.055544567388746025" EFFECT_SIZE="0.4500000000000002" ESTIMABLE="YES" MEAN_1="2.7" MEAN_2="2.25" ORDER="228" SD_1="0.75" SD_2="0.64" SE="0.20125646987529783" STUDY_ID="STD-Jaeschke-1991" TOTAL_1="24" TOTAL_2="24" WEIGHT="48.816674257302296"/>
<CONT_DATA CI_END="0.72010225775478" CI_START="-0.6401022577547799" EFFECT_SIZE="0.040000000000000036" ESTIMABLE="YES" MEAN_1="2.81" MEAN_2="2.77" ORDER="229" SD_1="0.99" SD_2="0.84" SE="0.34699732399132827" STUDY_ID="STD-Light-1975" TOTAL_1="14" TOTAL_2="14" WEIGHT="16.42160642060988"/>
<CONT_DATA CI_END="0.8697559529644564" CI_START="-0.30975595296445635" EFFECT_SIZE="0.28" ESTIMABLE="YES" MEAN_1="2.04" MEAN_2="1.76" ORDER="230" SD_1="0.79" SD_2="0.68" SE="0.3009014235038889" STUDY_ID="STD-Shah-1983" TOTAL_1="12" TOTAL_2="12" WEIGHT="21.838329059145675"/>
<CONT_DATA CI_END="0.8666441153274453" CI_START="-0.6666441153274452" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="2.79" MEAN_2="2.69" ORDER="231" SD_1="0.84" SD_2="0.72" SE="0.3911521443121589" STUDY_ID="STD-Silins-1985" TOTAL_1="8" TOTAL_2="8" WEIGHT="12.92339026294215"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>